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Abstract 
 
Since cancer is an extremely heterogeneous disease of origin, scientists are always 
trying to define novel approaches that can eliminate this disease. Over decades now, 
surgery, radiotherapy and chemotherapy have been the conventional methods to 
eradicate cancer. Unfortunately, cancer resistance has developed, in which tumor cells 
became resistant to the majority of chemotherapeutics. Consequently, people started to 
use combination therapy as a more intensified protocol to counteract the aggressiveness 
of cancer. However, the results are not satisfactory till now and lots of optimizations are 
needed in order to make sure that synergistic not antagonistic effects are happening. 
That is why scientists started to revisit cancer immunotherapy field after long years 
of its discovery. They are trying to understand more about the manifestations that occur 
in case of tumor induced immunosuppression. They are rapidly defining new approaches 
for harnessing the immune system against cancer. Different methodologies are 
developed in the last ten years, yet optimizations are still in process. The significant 
hurdle in the field of cancer immunotherapy is the selectivity towards certain immune 
cell population. In other words, how selective targeting could be achieved with high 
affinity to the cell of interest. That led to the evolution of cancer nano-immunotherapy 
where nanoparticles are engineered in a certain manner that can elicit a selective 
interaction with the target receptor. Many studies have revealed how nanotechnology is 
a promising tool in harnessing immune system against cancer.  
However, targeting as a technique is still paving the way for the optimum particle-
cell interaction. In the current study, we are paving the way to target immune cells 
infiltrating the tumor. The challenge here is that the population of cancer cells 
themselves are much more than the immune cells. In this study, the response of different 
immune cell lines towards internalization of different surface charged lipid-based 
nanoparticles (NPs) was investigated at different time frames. The hypothesis is whether 
specific immune cell line isolated from melanoma tumor model and lymphoid organ like 
spleen could be targeted with liposomes having different surface charges, could this be 
considered a novel approach for targeting immune cells passively depending only on 
surface charge.  
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In the first part, three sets of fluorescently labelled nano-liposomes were engineered 
as a model for different surface charges, the cationic DOTAP NP, anionic DOPG NP 
and near neutral DOPC NP with mean diameter of 220, 190, 210 nm and Zeta Potential 
of +36, -48 and -17.4 mV respectively. Physical stability of the NPs was evaluated by 
monitoring the changes in size and zeta potential. B16 melanoma cancer model was 
induced subcutaneously in C57BL/6 black mice (10 weeks age), divided into four 
groups each of five mice. CD11c Dendritic Cells (DCs), CD11b macrophages, CD90.2 
T-cells and CD49b Natural Killer (NK) cells were isolated from the tumors and spleens 
of each group. The three sets of NPs were tested against the isolated cell lines. The 
cellular uptake (internalization) was assessed by normalizing the fluorescence of the 
cells against their protein concentration, then all samples were acquired to flow 
cytometry, and shifts in fluorescence histograms on horizontal axis were monitored 
against PE channel on the vertical axis. Results reveal the presence of preferential 
internalization of specific surface charge over others in some cell lines in different time 
frames. For the first time differences in the internalization pattern are reported in the 
same immune cell line isolated from two different contexts tumor and spleen. These 
results might serve as a guideline for a rational design of successful nano-carriers that 
can maximize the targeting, and hence the therapeutic efficacy towards certain 
population of immune cells.  
In the second part and in the sense of screening the different pathways that 
contribute to immunosuppression, STAT3 (Signal Transducer and Activator of 
Transcription 3) pathway is considered one of the promising targets that when inhibited 
will reverse the immunosuppressed status of DCs. The molecular STAT3 inhibitor is 
investigated for the first time for its ability to offer superior properties in terms of 
specificity of STAT3 without affecting the other STATs and eliciting 
immunomodulatory effect. Pegylated nano-liposomes were synthesized with size of 190 
nm loaded with conjugated form of the drug which is drug-cholesterol in order to 
maximize the loading efficiency reaching 82±4% and physical stability with minimal 
changes in size and zeta potential. Cryo-TEM revealed the formation of predominant 
unilamillar structures. The efficacy of conjugated drug-NP was evaluated in-vitro on 
different cells: Bone Marrow derived DCs (BMDCs), DC cell line, B16F10, 4T1 and 
MDA-MB-231. The BMDCs primary cultures were generated from bone marrow of 
C57BL/6 mice femurs. The purity of CD11c lineage of BMDCs was assessed by flow 
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cytometry and showed 70-80% purity. In order to mimic the tumor microenvironment 
surrounding DCs in the tumor i.e. induce immunosuppression and downregulation of 
DCs surface receptors, high levels of phospho-STAT3 (pSTAT3) were induced via 
conditioning DCs with different conditioning media of B16, LLC, and 4T1. It has been 
revealed that B16 conditioning media induced the highest amount of pSTAT3 based on 
western blot, flow cytometry and cytokine analysis. DCs by then showed 
downregulation of CD80, CD86 and major histocompatibility complex class II 
(MHCII). Finally, the drug-NP and free drug (5µmole) were added to the 
immunosuppressed DCs for 24hrs and maturation status was assessed using flow 
cytometry. Expression of CD86, MHCII and CD80 were evaluated after gating CD11c 
double positive population. No significant change was observed in case of CD80. Slight 
increase was observed in case of CD86. However, surprisingly there was a dramatic 
increase in MHCII with 3 folds higher expression in case of free drug and 1.3 fold with 
drug-NP in only 24 hrs, this reflects sustained release of the drug from the NP. These 
results demonstrate the potential of the STAT3 inhibitor in reversing the 
immunosuppressed status of DCs in tumor microenvironment and its 
immunomodulatory role for the first time. 
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Chapter one 
1. Introduction and scope of the thesis 
 
1.1 Cancer immunotherapy from the very beginning 
 
Cancer immunotherapy is meant to manipulate the immune system against cancer 
as a different therapeutic strategy in oncology field. In the 19th century, scientists noticed 
the co-incidence of erysipelas infection along with cancer regression. In 1868 
specifically, a German scientist successfully treated neck carcinoma after inoculation of 
erysipelas extract (cutaneous bacterial infection) intra-tumoral. The exact mechanism 
by then was still unrevealed, but it was clinically proved that upon pathogen injection 
in cancer patients the body develops a kind of reaction that helps counteracting the tumor 
growth leading to its eradication. After world  war II, significant immunological 
discoveries have evolved while studying mice tumor models such as the definition of 
major histocompatibility complex ( MHC), dendritic cells ( DCs), etc.1 In 2001, there 
was a major breakthrough in the field of cancer immunotherapy, when three teams 
published in Nature Genetics the discovery of FOXP3 which is expressed on CD4+ T 
cells known as Tregs. After that, Tregs were not only known with their immune self-
tolerance, but also immune cancer tolerance.2   
Our immune system in its simplest form consists of mesh of cells and lymphoid 
organs, they all together provide our body with protection against infectious microbes 
and might also help in counteracting developing cancer in a way or another. 
Anatomically our immune system on the organ level embrace two types of organs; 
primary lymphoid organs including bone marrow and thymus, secondary lymphoid 
organs including spleen, lymph nodes, Peyer’s patches and mucosal associated 
lymphoid tissue.  On the cellular level, there are two components, innate immunity and 
adaptive immunity. Innate immunity such as neutrophils, macrophages and natural killer 
cells are responsible for mediating reactions against infections at entry portals like skin 
and mucosal surfaces. Adaptive immunity on the other hand needs time to respond to a 
certain trigger like (T-cells and B-cells), they have the ability to differentiate into 
memory cells that can act upon certain trigger in case of re-infection. 3,4,5 
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Tuning the immune system today is becoming of a great interest due to the prevalent 
rule of the immunity in case of encountering any disease. Today, one of the most 
effective therapeutic intervention is vaccination. However, vaccine technology up till 
now remains abstract in front of some infectious diseases such as malaria, HIV, hepatitis 
C and tuberculosis. Our context here is concerned with cancer immunotherapy which 
mainly deals with manipulation and stimulation of the immune system to constrain and 
hopefully eliminate a specific tumor. Putting in consideration that not usually activated 
immune system do the job the right way, sometime times it might attack self-healthy 
tissues in a process known by autoimmunity. 
 
1.2 Paradigm Shift: targeting immune cells instead of cancer cells 
 
Curing cancer was and still is one of the biggest challenges in the human related 
diseases facing the whole medical community. To date, cancer therapeutics have been 
mainly depending on a combination strategy, i.e. surgery, radiotherapy and the cytotoxic 
chemotherapeutics. Not to mention that all the previous strategies are conventional and 
approved, but rather old. The first known radical breast cancer mastectomy was 
performed in 1773, and since then, this kind of surgery practice spread worldwide.6 
After that, radiotherapy has been performed for the first time in 1896.7 The 
revolution of cytotoxic chemotherapeutics in the 1930s was in a continuous 
development, especially during World War II and with using Nitrogen mustard8. Later 
on, a lot of collaborative efforts were able to find the best possible combinations with 
the best optimized protocols through running thousands of randomized clinical trials on 
cancer patients. However, the outcome of these combinations was not optimum and did 
not provide improvement in terms of survival rates in some cancers such as glioblastoma 
and lung cancers. In addition, these combination therapeutics showed awful side effects 
because of their high toxicity profiles. That is why the majority of cancer research 
directions in the last 20 years have been focusing on finding solutions that can provide 
better selectivity to cancer cells and less toxicity to healthy cells.9 
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The progress that has been made in biochemistry field allowed the proper 
engineering of small molecules that can specifically bind to over expressed proteins in 
cancer cells and inhibit certain oncogenic activity. This targeted protein could be 
membrane receptors, intracytoplasmic or intranuclear.10 In the best case scenario, this 
small molecule will be able to inhibit that specific pathway which is responsible for 
tumor cell proliferation. Actually, this situation represents ideal type of cancer that 
originates from a single driver mutation and is able to respond to single monotherapy.  
But actually, most cancers have multiple mutation origin, and therefore, this necessitates 
the design of multi-targeted therapy.11 
Apart from therapeutic inventions via vaccination, there is an increasing demand to 
monitor and measure the status of the immune system which makes the thing more 
complicated, because of the complex nature of the immune system that is disseminated 
all over the body making the clinical analysis a major hurdle.12–14 Figure 1.2-1 illustrates 
the important basic immunological discoveries and key clinical trials for cancer 
immunotherapy since 1898. 
                                   
 
 
 
      
 
 
 
 
 
   
 
Figure 1.2-1 Cancer immunotherapy timeline (reproduced) 1 
Figure 1.2-1 
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1.3 Tumor microenvironment 
 
The fact that cancer is by nature of extremely heterogeneous origin and coupled 
with immunosuppression caused by the presence of the tumor itself and its 
microenvironment represented in the tumor derived factors (TDFs), indicates the extent 
of hurdles new therapies are facing in the oncology field. The objective of the new 
therapeutic modalities is to act against cancer taking into account that this will not 
happen unless the status of the immune system is restored in a away like inhibiting the 
signals coming from the immunosuppressive microenvironment. This objective actually 
suggests the concept of having combination of multimodal therapeutics that can target 
more than one trigger at the same time.  
Our immune system play a critical role in any cancer progression in a process called 
immunoediting which comprises three phases; first is elimination of cancer cells by 
domination of immunosurveillence, second is the equilibrium where the surviving 
cancer cells acquire a kind of resistance to elimination and then proceed to the third 
escape phase where they escape and continue to grow in an uncontrolled manner and 
eventually get promoted to malignancy.15,16 
 
1.4 Immuno-suppression mechanism 
 
Tumors have their own ways to circumvent the immune attack by different 
immunosuppressive mechanisms, most of them work in parallel to each other. Mediators 
like prostaglandin E2, adenosine VEGF and TGF-β influence the whole tumor 
microenvironement scene through direct and indirect immunosuppressive impacts. 
These derived factors affect the whole immune orchestra through multiple smart ways, 
they can hinder from DCs maturation and turn them tolerogenic instead of immunogenic 
thus affecting the efficient priming of T-cells and indirectly inhibiting their penetration 
capabilities into the tumor bed, or directly inhibiting either by disturbing the effector T-
cell activation or promoting the regulatory T-cell expansion. i.e. when tumor cells 
produce adenosine under hypoxic conditions, they suppress the T-cell activation while 
enhancing the Treg expansion. VEGF also contributes to the suppression of proper T-cell 
5 
 
function and development.17  Tumor cells can also evade the T-cell priming through the 
tumor derived factors that can directly contribute to MHC down regulation or through 
disturbing any other component in the machinery of antigen processing. Not only that, 
but tumor cells have the ability to develop special surface ligands that can help them 
induce anergy or exhaustion to the T-cells like PD-L1. The tumor itself comprising the 
tumor microenvironment is infiltrated by a variety of immunosuppressive subsets of 
leukocytes in addition to those Treg cells. It has been noticed that their extent of  
infiltration is always correlated to the poor diagnosis.18 Myeloid derived suppressor cells 
(MDSC) also have their impact in tumor immunosuppression. Their mechanism still not 
well understood, however the suggested explanation is based on their contribution in 
several mechanisms such as reactive oxidative species, nitric oxide, IL-10, arginase and 
TGF-β and some reports suggested that MDSC directly induce Treg expansion. Tumor 
stromal cells as well play an important role as we know in tumor expansion, but in our 
context here they have immune-modulatory roles, they promote recruitment of 
immunosuppressive cells that suppress effector T-cells. All the previous indicates that 
further studies are needed in order to determine which of these mechanisms has the most 
immunosuppressive effects and which of these mechanisms can barely determine the 
immune status of the patient.19  
To date, our understanding to the events that govern the generation and regulation 
of anti-tumor immunity suggests that the possible routes for therapeutic intervention 
will be either promoting the efficiency of antigen presentation through antigen 
presenting cells specially the professional ones like DCs and promoting production of 
effector T-cells or overcoming to some extent the immunosuppression in the tumor 
microenvironment. The first stimulus that triggers the whole orchestra begins with 
capturing a tumor antigen by APC. This captured antigen will be cross presented on 
MHC and then home to the lymph node. Important thing to mention is the context where 
the antigen was captured and presented. If the previous incidence happens in the 
presence of immunogenic maturation stimulus, DCs will have anti-tumor effector 
response through T-cells, and if such stimulus is not received, DCs will elicit tolerance 
that leads to effector T-cell anergy and production of regulatory cells. It is important to 
mention also that the immune response elicited to T-cell depends on the status of DC 
maturation and mode of interaction of T-cells co-stimulatory moieties with DC surface 
receptors.20 
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Figure 1.4-1 reveals how immunotherapy catches most of the cancer research 
groups’ attention. In 2014, immunotherapy was surprisingly ranked number one ahead 
of targeted chemotherapy and gene therapy that have been dominating the cancer 
research field for decades. This fact reflects how immunotherapy is representing the 
future trend for cancer therapies. Also, in the same year the percentage of drug approvals 
in oncology field constituted 22% as shown in Figure 1.4-2. 
 
 
                       Figure 1.4-1  Rank of different clinical research areas in 2014 ( reproduced ) 21      
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            Figure 1.4-2  Drug approval categorized by therapeutic area in 2014 ( reproduced ) 22 
  
1.5 Different strategies to harness the immune system against cancer 
 
Over decades great efforts have been made to treat cancer using the immune system, 
although this dates back over almost a century but the progress is still slow. Recently, 
many clinical trials showed success in the induction of anti-tumor immune response and 
this success provided an incremental improvement in the field. Generally, the 
approaches that can be used for anti-tumor immune response induction are categorized 
into two main categories; antigen specific and non-antigen specific. Antigen-specific 
comprises adoptive cell transfer of autologous cancer specific cells and different 
therapeutic vaccination techniques, whereas non-antigen specific strategies comprise 
non-specific immune stimulation and immune check point inhibition as well. 23 
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1.5.1 A) Non-specific immune stimulation 
 
Immune cell stimulation such as T-cells and APCs like DCs can be achieved in a 
non-specific way either via their stimulation or via depletion (inhibition) of 
immunoregulatory cells like Treg cells. Cytokines such as IL-2 and INFα can be used to 
stimulate effector T-cells. These cytokines are already approved for the treatment of 
renal carcinoma and melanoma. Complete remission has been observed with IL-2 
treatment in selected melanoma patients. However, still there are limitations that hinder 
from their common use due to the toxicity that is associated with their prolonged use. 
Other approaches aim at full activation of APC using adjuvants like TLR ligands, for 
example imiquimod is a TLR7 agonist that has been approved for basal cell carcinoma 
treatment. For bladder cancer, BCG adjuvant has been considered as a standard therapy 
and approved for this type of cancer. Treg cells have been inhibited by targeting the IL-2 
receptor with daclizumab antibody (anti-CD25) or low dose cyclophosphamide 
(chemotherapeutic) as shown in Figure 1.5-1. It is worth saying that specificity of these 
approaches still representing major challenges. There are other targeted anti-cancer 
drugs and chemotherapeutics that have the ability to induce immunogenic apoptosis and 
cause immune-stimulation or inhibition of suppressive cells or interfering with the 
inhibitory pathways. Novel treatments that can fully harness the immunogenic 
properties of the proposed drugs need to be further addressed. 23       
        
 
 
 
 
 
  
Figure 1.5-1  Examples for the non-specific immune stimulation that might occur with T-cells and 
APCs. 23 
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1.5.2 B) Immune checkpoint blockage 
 
Figure 1.5-2 illustrates the cross talk between the T-cell and APC or tumor cell, 
specifying the possible receptor interactions that play significant role in down-
modulation of T-cell activity through its recognition for the processed antigen on the 
MHC molecule. By blocking those immune-checkpoints, the overall T-cell status will 
be either activated or showing better survival. The CTLA4-B7 is one of the major 
interactions that dictate the pattern of the T-cell response. Also, the PD1-PDL1 
interaction represents a prominent role in the effector phase of the T-cell. Ipilimumab 
which is a CTLA4 antibody has been approved for metastatic melanoma. Immune 
checkpoint blockage approach is considered one of the less costly and less laborious 
since it does not depend on the concept of personalized medicine, in other words, it is 
not tailored according to the patient. This fact gives this approach a privilege than 
adoptive cell transfer or cellular vaccine, but there will be always a risk from 
development of autoimmune response. 23 
                       
Figure 1.5-2  The interaction between T-cells and APCs specifying the possible receptor 
interaction23 
 
 
10 
 
1.5.3 C) Adoptive cell transfer 
 
Effector cells can be isolated from the patient, carefully selected and then expanded 
while ex-vivo. These expanded cells can be re-injected as such into the patient without 
being exposed to antigen or get activated in case of APCs. There are two major strategies 
that are being addressed these days as illustrated in Figure 1.5-3. The first is after 
resection of the tumor and most probably it will be melanoma, T-cells infiltrating the 
tumor will be isolated and cultured outside, whereas they get expanded ex-vivo when 
they get incubated with IL-2. After getting enough population from the polyclonal T-
cells, they are re-injected again to the patient. The second strategy is to isolate T-cells 
from peripheral blood. Then via genetic engineering, the T-cells will get modulated and 
become expressing TCRs which are tumor antigen specific followed by re-infusion to 
the patient. The advantage of this strategy is that good count of T-cells can be isolated 
and re-infused into the patient, while the potential disadvantage is that the genetically 
engineered T-cells might express limited antigen specificity repertoire. 23    
                   
 
 
 
 
 
 
 
  
  
 Figure 1.5-3  Major strategies for adoptive cell transfer23 
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1.5.4 D) Different vaccination approaches 
 
The primary aim of designing immunotherapeutic vaccines is to introduce the tumor 
antigen in an appropriate context that can efficiently prime T-cells. In other words, is to 
educate the T-cells through proper presentation from the APCs stimuli signals. Tumor 
antigens can be obtained in form of synthetic peptides or protein or even encoded by 
virus or plasmid DNA. Also, some idiotype antibodies have been recognized for their 
tumor specificity and are used as tumor vaccines. Another strategy that can help us 
circumvent the need to identify the specific antigen for each tumor is direct extraction 
from the tumor, whereas tumor cells will be isolated and irradiated then re-administrated 
to the patient. On the other hand, APCs themselves can be isolated from the patient 
blood stream, expanded, activated by adding adjuvants or cytokines, loaded with antigen 
then re-administrated to the patient. The previous strategy was used in the development 
of prostate cancer vaccine sipuleucel-T. It is worth saying that tailor made vaccination 
approaches are tedious and expensive, in addition they require extremely complex 
production procedures. These challenges hinder from the progress in this field seeking 
a complete response23 as summarized in Figure 1.5-4. 
 
  
 
                                                                                             
 
 
 
 
 
 
                                                Figure 1.5-4  Possible vaccination strategies23 
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1.6 Nanotechnology and immune system 
 
Today with the privilege of being able to synthesis extremely small particles in the 
nano-range and make use of nanoscience and nanotechnology, we can reach superior 
properties than the bulk scale. Nanoparticles have their own physicochemical properties 
that make them promising in the field of cancer immunotherapy in form of drug delivery, 
diagnostic and theranostic modalities. Since nanoparticles are of a near range to immune 
cells diameter, they can interact with the immune cells, bind to the surface and then get 
internalized. Different nanoparticle characteristics will govern the way of interaction 
with the immune cells. If a specific immune cell needs to be targeted, the ideal 
nanoparticle will keep its integrity without being disturbed by the complex biological 
environment.24 In the current study we will investigate the possibility of using nano-
liposomes to target different immune cells in different contexts.  
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1.7 Scope of thesis 
 
Lipid based nanoparticles like liposomes have been grabbing attention in the 
medical field due to their near zero toxicity, biodegradability and their approval by the 
FDA as drug delivery carrier. A critical field like cancer immunotherapy deals with a 
very sensitive and delicate type of cells which are immune cells. Consequently, any 
therapeutic intervention requires high level of integrity and selectivity to avoid any mess 
that could happen in the immune system. The hypothesis here is whether nanoliposomes 
with different surface charges can show different internalization pattern with different 
immune cell lines in different time frames and whether pegylated nanoliposome can 
play immunomodulatory role in DCs.  
Chapter 2 The first part gives a general overview on how and what nanoparticles can 
alter the immune response. How tailoring nanoparticles affect mode of interaction. 
Examples on particulate vaccines and background on liposomes. The second part gives 
an overview on dendritic cells. How cancer can cause suppression of their functional 
maturation. Current strategies to modulate and reprogram this suppression. A promising 
drug like LLL12 and its potency to fix the improper signals. 
Chapter 3 The first part gives details of experimental methods regarding synthesis, 
preparation, characterization of fluorescent labeled nano-liposomes and their 
internalization testing against ex-vivo model immune cell lines. The second part gives 
details of experimental methods regarding synthesis, preparation characterization of 
LLL12-pegylated liposomes and their testing against bone marrow derived dendritic 
cells. 
Chapter 4 presents the results and discussion concerning the internalization of 
fluorescent labelled liposomes, their uptake efficiency and flow cytometry analysis.  
Chapter 5 presents the results and discussion concerning the ability of LLL12-
pegylated liposomes to reprogram the downregulated dendritic cells (proof of concept).  
Chapter 6 conclusion and future perspectives.  
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Chapter two 
2. Review of relevant literature  
 
2.1 Micro and nanoparticles for tuning immunity 
 
Our immune system could be the major cause of a disease or the major cause of 
curing this disease, in the sense of either acting against cancer or acting on a tissue 
causing destruction in case of autoimmune diseases. That is why there is always a need 
to suppress or amplify this immune reaction. Recently, great work has been done in 
creating novel designs in micro and nano-particles that can deliver drugs, imaging 
agents or have the ability to stimulate immune cells through their chemical and physical 
properties. This will lead to the development in vaccine delivery, immune response 
promotion against tumors or suppression in case of autoimmunity. 
Synthetic micro and nano-particles play a major role in solving out a lot of hurdles 
cancer immunotherapy is facing today. Nanoparticle engineering comprehensively 
addresses delivery systems and adjuvants in vaccines and diagnostic agents to be able 
to study ongoing immune responses while ex-vivo expansions monitoring. By nano-
biotechnology a lot of applications could be tailored in the sense of addressing diverse 
conditions with major implications on the health care sector. 25–27 
2.2 Tailoring particle interactions on a single-cell level 
 
Cells are communicating to each other on a single base level, their membrane 
characteristics play a major role in their function and dictates how they will react with 
the surrounding environment. One of the most crucial cell-cell interaction that will 
eventually trigger an immune response is priming T-cells through one of the major 
APCs; macrophages or dendritic cells. Nanoparticles can be designed in a way that they 
can present receptors, functionalized with ligands and co-ligands and be able to mimic 
the activated APC leading to T-cell efficient priming. What makes nanoparticles of a 
great interest in this context is that they can entirely replace the APC and be used directly 
in adoptive therapy and vaccine technology. By modulating nanoparticle properties like 
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size, surface charge, shape and elastic properties, the cellular uptake and degree of 
internalization will differ and provide optimized drug delivery platform.28 
The contact between DCs and T-cells is presented in what is known by 
immunological synapse. The DCs will capture the pathogen fragment and display its 
peptide (antigen) to the T-cells through establishing the MHC. DCs are professional 
APCs, they can determine the efficiency of the immune response towards a particular 
trigger through instructing T-cells, they can instruct T-cells via co-stimulatory ligands, 
after which soluble cytokines are released at the synaptic cleft.28,29                                                                                         
Since that DCs play a major role in the response of the adaptive immunity, scientists 
thought of designing micro and nano-particles that can entirely mimic the surface of the 
DCs and have the ability to establish a good contact with T-cells. This method will 
provide an artificial stimulation for T-cells either in-vitro or in-vivo. Recently, 
engineering of multifunctional artificial APC such as biodegradable poly (lactide- co -
glycolide) (PLGA) conjugated with avidin-palmitate is considered a kind of surface 
modification that allows the decoration of the particle with stimulatory ligands. It has 
been noticed that when this type of delivery system is incubated with T-lymphocytes 
using two different sizes one in micro range and the other in the nano range but having 
the same co-stimulatory ligands, the larger micro-particle shows better 
internalization.30,31 
 
2.3 Role of particle shape 
 
After the incredible advances in the micro and nanotechnology in the biomedical 
field especially in immunity modulation, there has been a growing interest to study how 
and what are the properties that govern the overall efficacy of a delivery, in terms of 
binding and internalization within immune cells like macrophages. This eventually aims 
at unrevealing a magic particle that can resist phagocytosis. Engineering particle surface 
chemistry in a way that can block the protein adsorption and hinder from any subsequent 
interaction in a process called opsonization requires much effort from the scientists. The 
most common strategy to counteract this opsonization process is the particle pegylation, 
anchoring a layer of poly-ethylene-glycol (PEG). PEG creates steric hindrance on the 
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surface of the particle that ends up by resisting protein interaction. Recently, it has  
become obvious that not only the surface chemistry dictates how the particles will 
interact with the phagocytes, but also geometrical shape and mechanical properties show 
a significant role in deciding the fate of the particle.32,33 
It has been shown that the isotropic particles show enhanced internalization than 
the anisotropic particles that was reasoned by the incomplete actin formation along the 
length of the anisotropic geometry. But, there is always an interplay between cellular 
response and particle geometry, for example HeLa cells showed much more efficient 
internalization with rod-like high aspect ratio shapes. These contrasting differences arise 
from different endocytic/phagocytic pathways, meaning that there is a preferential 
internalization pathway than another according to the cell type. Uncoated silica particles 
with different shapes (disc, sphere, and cylinder) but almost same volume revealed that 
disc shape showed higher accumulation in lungs than liver compared to spheres.34  
In case of poly (maleic anhydride) / lipid particles, higher uptake of irregular shaped 
nanoparticles 350 nm took place in spleen more than spherical shapes of similar size 
and composition. To sum up, these studies confirm that shape is an important factor, and 
a good attention to the design should be taken in consideration, especially if we need to 
target or avoid APCs in different organs.35   
2.4 Micro- and nano-particle vaccine 
 
Modern vaccine technology put a lot of effort to design a purified antigenic subunit 
that can provoke certain immune response and circumvent the dangers associated with 
the live attenuated vaccines. However, the limitation of purified antigenic subunit lie in 
the weak immune-response they can provoke, which requires the addition of adjuvants. 
The primary target of vaccine is APC since they have an efficient ability to initiate and 
sustain cellular and humoral immune response. DCs in particular are recognized by their 
strong ability in priming T-cells.36,37 DCs can process antigen through MHC molecules 
in the cross-presentation process. Vaccines can be injected intradermaly or 
subcutaneously, drain through lymph nodes to DCs or get internalized directly at the 
injection site. Once the antigen get internalized by APCs like macrophages or DCs, it 
will be processed on the MHC molecule. The features of the nanoparticulate antigen 
should be designed such that can rapidly release antigen onto the MHC once it get 
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internalized before being digested by the acidic endosomal media, as there is a narrow 
time frame between both actions. 
 
2.5 Liposomes  
 
Lipid-based nanoparticles like liposomes constitutes a membrane of self-assembled 
lipid bilayer, their sizes range between 90 to 200 nm. Liposomes are mainly formed of 
phospholipids and cholesterol that surround the aqueous portion, Figure 2.5-1. 
Phospholipids are characterized by their hydrophilic heads and hydrophobic tails. That 
is why this type of nanoparticles provide flexible platform for almost all kinds of 
molecules, since they have a unique nature that allows them to either encapsulate 
hydrophilic molecule within the inside compartment or entrap hydrophobic molecule in 
the outer compartment within the hydrophobic bilayer.38  
These superior characteristics of liposomes rendered them a great potential for a 
successful drug delivery platform, based on the fact that they elicit slow or sustained 
release kinetics that is reflected on the therapeutic aspect in the sense of improved 
accumulation of the entrapped compound. On the other hand, they narrow the toxicity 
profile of the entrapped compound since they limit and control the biodistribution 
pattern.39 Taking into consideration that liposomes have the basic requirement for a 
nanoparticle to be considered from the first nanoparticles that are FDA approved, as 
they are biocompatible, biodegradable, and owing to their lipid nature they have the 
ability to cross the membranes. Liposomes have been recommended and used as a safe 
delivery platform for vaccines, chemotherapeutic drugs, and gene therapy.40 While it is 
important to mention that one of the major challenges of the conventional liposomes is 
their short circulation time. That is why long circulating liposomes or stealth liposomes 
have been established to circumvent this problem. Those modified liposomes are 
designed in such a way they have steric effect that contributes to prolonged half life 
time. 
Since liposomes are FDA approved and they have proven their superior 
characteristics, they reached advanced clinical trials. Examples for their use as anti- 
cancer platform are the liposomal doxorubicin, cisplatin and cytarabin. Liposomal 
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doxorubicin reduced to a great extent the side effects that were usually associated with 
this drug like renal damage and heart failure. Liposomes also act as a good candidate 
for entrapping oligonucleotides such as siRNA.  
Cancer vaccine targeting DCs and DNA complexes has been reported for its 
formulation based on liposome with great anti-tumor immunity. In addition, liposomes 
are now  studied as a carrier for contrast agents, they offer a safe biodegradable platform 
for in-vivo multi-color MRI for mapping the lymph node.41   
   
                                                 Figure 2.5-1 Liposome structure42 
 
2.6 Effect of surface charge on cellular uptake 
 
Engineering a nanoparticle that has targeting ability can be achieved by two ways 
either active targeting, where the nanoparticle is functionalized by a certain ligand that 
has binding affinity to the receptor of interest. Or by making use of the natural properties 
of the nanoparticle and utilize the passive targeting strategy, where we can play with the 
particle physicochemical properties in order to target certain population than other, 
Figure 2.6-1. Physicochemical properties like size, shape and surface charge directly 
affect the uptake behavior that differs from one type of cell to another one. Particulate 
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system with different surface charge will elicit different pharmacokinetic patterns. A 
step before internalization should first takes place which is binding or attachment. The 
way and degree of attachment vary according to the surface charge. Consequently, 
playing with particle surface charge could control binding to specific tissue or cell.43 
Liposomes can be categorized according to their charge into three groups: cationic, 
which possess cationic group like amino group like DOTMA and DOTAP liposomes. 
They showed superior transfection ability in both in-vitro and in-vivo experiments. 
                     Figure 2.6-1 illustrates the targeting approaches: Passive and Active44 
Anionic, which possess anion group like DOPG and neutral or zwitterionic that 
has both charges like DOPC and DPPC, structures are shown in Figure 2.6-2. Here we 
are trying to test whether there will be preferential internalization of certain surface 
charge within certain immune cell line in ex-vivo cell lines. 
                                              Figure 2.6-2 Structures of different lipids45 
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2.7 Dendritic cells and STAT3 
 
In order to have and maintain proper and adequate immune response, there should 
be healthy and functioning bone marrow derived APCs. One of the characteristics of 
cancer is the abnormality that happens in the myeloid lineage. This abnormality is 
symbolized in two major manifestations; accumulation of the immature myeloid cells 
and most importantly is the defective differentiation and maturation of the most 
professional APCs, dendritic cells. Presence of malfunctioned DCs with high numbers 
impair from the proper antitumor immune response.46,47 In other words, decreased 
numbers of mature DCs and accumulation of immunosuppressive myeloid cells 
contribute to the development of immune tolerance. All these events help in the 
development of tumor escape from the control of the immune system. It is well known 
that the factors that mediate the abnormal differentiation of the myeloid lineage is the 
infiltration of the tumor derived factors such as; IL-6, IL-10, TGF-β, VEGF, etc.48,49   
A major challenge that cancer immunology is trying to understand is how tumor 
cells have the ability to elicit a global shutdown for the immune stimulating mediators 
or signals in the sense of cytokine or stimulatory molecules in the tumor 
microenvironment.50,51 The suggested scenario is that these elicited effects take place 
locally because generally cancer patients do not experience systematic 
immunosuppression except those of late stage. The question now is what are the 
mechanisms that make the tumor cells produce immunosuppressive factors that later on 
render tolerogenic DCs ?52,53 what makes cancer cells dominate the immune cells and 
take the control over them in the sense of angiogenesis, survival and invasion? If we 
managed to understand the signaling pathways for tumor microenvironment regulation, 
we will be able to identify targets for cancer immunotherapy.54 Recently, scientists 
identified an important signaling pathway that acts as a mediator in tumor 
immunosuppression which is STAT3; signal transducer and activator of transcription 3. 
55,56 STAT3 is considered a negative regulator to T helper cells and potent activator for 
immunosuppressive genes. STAT3 mediates the crosstalk between tumor cells and 
immune cells, this happens upon its activation via tumor derived factors such as IL-6, 
IL-10, etc., these events lead eventually to immunosuppression. Owing to all previous 
reasons, STAT3 is considered a potential target for cancer immunotherapy.57,58 
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2.8  STAT3 biology 
 
In normal state, STAT3 pathway regulate gene expression of proliferation, survival, 
migration and invasion in addition to angiogenesis. STAT3 plays role in embryo 
development at his early stages. Normally, STAT3 is under controlled regulation so that 
signals are only within the physiological response in benign cells.59,60 Activation of 
STAT is associated with Janus kinases (JAKs). JAKs are phosphorylated by cytokines 
or signals such as TNF, IL-6, EGF, TGF-β,etc,61,62consequently the phosphorylated 
JAKs initiate cascade of multiple phosphorylations to the tyrosine residue of the 
cytokine receptor within the cytoplasmic domain.63,64 Unphosphorylated monomeric 
STAT get recruited to the activated sites through interaction between the 
phosphotyrosine domains at the activated receptors and the SH2 domain of STAT. 
Consequently, JAKs phosphorylate the tyrosine of STAT domain at C- terminal. Finally, 
STAT gets separated from the receptor and undergoes dimerization to other STAT 
monomers then translocate to the nucleus and binds to the DNA in the promoter of the 
target genes.65,66 Pathway is shown in Figure 2.8-1.                                                                                    
               
  
 
 
 
 
 
 
 
                                                    Figure 2.8-1 JAK-STAT pathway67 
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2.9 Suppression of DC functional maturation 
 
It is well established that DCs are professional in inducing anti-tumor immune 
response, on the other hand when they experience stress from the tumor 
microenvironment, they fail to reach the maturation status and remain immature, 
showing insufficient expression levels of MHC class II, CD80 and CD86.52,53,68 These 
manifestations lead to failure of DCs to prime T cells, not only that but they can be 
involved in immune tolerance. Previous studies showed that STAT3 activity in tumor 
cells suppress DC maturation by affecting the expression of MHC class II. IL-6, IL-10, 
IL-12 and VEGF mediated the STAT3 inhibitory action on DC maturation. Studies 
revealed that disrupting signaling of STAT3 leads to activation of T-cells.69 
2.10 STAT3 signaling and immune cells 
 
Scientists investigated whether STAT3 signaling is critical to induce inhibitory 
actions on DC maturation. They reported that blocking STAT3 signaling either by 
interfering with the STAT3 gene itself or by using STAT3 phosphorylation inhibitors, 
abolished the inhibitory effects on DC functional maturation and showed decreased 
numbers of immature CD11c-CD86 and CD11c-CD80.69 In agreement with the 
previous studies, it has been reported that when tumor derived factors induce STAT3 
signaling in immature myeloid cells, they prevent from their differentiation to mature 
DCs.70 Accumulation of immunosuppressive population of myeloid cells is partially due 
to STAT3 activation. It has been shown also that IL-6 mediates inhibitory effect on DC 
maturation through being STAT3 dependent.71 
 
2.11 Inhibition of STAT3 in the preclinical trials in different tumors 
 
As mentioned before STAT3 has physiological functions that regulate biological 
processes, and high expression of phosphorylated STAT3 (pSTAT3) than normal 
contributes to malignant manifestations and immunosuppression. STAT3 targeting is 
becoming of a great interest and is representing a novel approach to prevent or treat 
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cancer. To target STAT3, there are several strategies that tackle the signaling pathway; 
a) Controlling the upstream negative or positive regulators, either by enhancing the 
negative STAT3 regulators or by inhibiting the positive ones. b) Utilizing RNA 
interference, which is an approach that affects translation of STAT3 mRNA using 
siRNA or anti-sense STAT3 oligonucleotides. C) Direct targeting of STAT3 protein and 
this approach is considered efficient since it directly inhibits STAT3 protein. STAT3 
has three domains: SH2, DNA-binding and NH2-terminal. These domains are 
considered potential targets for development of STAT3 inhibitor. Numerous novel 
molecular inhibitors that target SH2 domain were selected and designed via structured 
based virtual screening. These inhibitors also showed activity against STAT3 
dimerization and DNA-binding in cell lines and animal models.72 
In general, targeting STAT3 with small molecule inhibitors is the most promising 
approach for more than one reason. First, controlling the upstream regulators might not 
be able to block the STAT3 pathway due to the presence of multiple cross talkings and 
single targeted therapy might not be efficient. Second, RNA targeting still facing the 
problem of stable delivery issues, cell permeability and solubility of those 
oligonucleotides, thus clinical trials are still limited. Third, the preclinical data reveals 
that small molecule inhibitors are showing significant growth inhibition in cancer cells 
in-vitro and in animal models.73 
 
2.12 Novel small molecule, LLL12 
 
LLL12 is a small molecule that targets STAT3. It was found that LLL12 inhibits 
STAT3 phosphorylation at the tyrosine site. It has been tested with different cell lines; 
pancreatic, breast, and glioblastoma cells expressing high levels of pSTAT3. Studies 
showed that LLL12 as well has the ability to inhibit pSTAT3 induced by IL-6. The 
mechanism by which LLL12 inhibits STAT3 phosphorylation is by inhibition of DNA 
binding activity. Down regulation of downstream targets such as Bcl-2, Cyclin and 
survivin was also observed with LLL12.74 LLL12 showed higher potency than 
previously reported STAT3 inhibitors like WP1066 and S3I-201. LLL12 showed 
selectivity to STAT3 than STAT1 and STAT5 by specific inhibition of STAT3 DNA 
binding activity. This reflects how LLL12 is potent and specific to STAT3 owing to its 
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interaction with pTyr705 site of STAT3, consequently preventing STAT3 dimerization, 
translocation into the nucleus and blocking any possibility for STAT3 to be recruited to 
the target receptors.75 
 LLL12 has been recently identified in 2010 after making comparative screening 
for the most potent STAT3 inhibitors. It has been revealed that anthraquinones and 
naphthoquinones show preferential targeting activity against STAT3, among all 
anthraquinones based on SAR studies LLL12 showed a potent activity owing to its 
sulfonamide group at position 1 as shown in Figure 2.12-1.76 Previously, curcumin 
family showed good activity against STAT3, however this family showed off-target 
events together with STAT3 inhibition. On the other hand, LLL12 which is not a 
curcumin derivative showed selectivity towards STAT3.77 
                                   
 
 
 
 
                                                       Figure 2.12-1 LLL12 structure 
So far LLL12 is considered a promising agent for targeting cancer that express high 
levels of STAT3. Here we propose LLL12 to target immunosuppressed cells and helps 
restore the maturation inhibition that caused by high level of STAT3 expression in 
dendritic cells. To date, this is the first time LLL12 is used in the context of cancer 
immunotherapy.  
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Chapter three 
3. Materials and Methods 
 
3.1 First part: Synthesis of fluorescent labelled liposomes and testing 
them against ex-vivo cell lines 
 
3.1.1 Materials 
 
The Reactions were done under inert procedures. Cholesterol, Dichloromethane 
(DCM), unhydrous DCM, pyridine, methanol ethylenediamine, L-α-
phosphatidylcholine (PC) were bought from SigmaAldrich (MA, USA). NHS-
Fluorescein, Thermo Scientific (MA, USA). 1,2-dioleoyl-3-trimethylammonium-
propane [DOTAP], 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) [DOPG], 1,2-
dioleoyl-sn-glycero-3-phosphocholine [DOPC], 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine [DPPC], 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N- 
[Amino(Polythylene Glycol)2000] (DSPE-PEG-Amino), 1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N- [methoxy (Polythylene Glycol)2000] (DSPE-PEG-methoxy), 
1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N- [carboxy (Polythylene 
Glycol)2000] (DSPE-PEG-carboxy),      Extruder kit containing Whatman Nucleopore 
Membrane 0.2 μm, filter supports and 1.0 mL syringes were bought from Avanti Polar 
Lipids (MA, USA). Anhydrous dimethylformamide (DMF) was bought from Acros 
Organics. Thin layer chromatography (TLC) was performed using precoated aluminum 
with silica gel from Fluka Analytical (MA, USA). Spots on the TLC plates were 
visualized using alkanine permanganate. 1H NMR (300 MHz) spectrum was obtained 
on a Varian Mercury 300 spectrophotometer. The chemical shifts are expressed in parts 
per million (ppm) using suitable deuterated NMR solvents with reference to TMS at 0 
ppm. Column chromatography was conducted using silica gel (230-400 mesh) from 
Qualigens. 
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3.1.2 Synthesis of Cholesterol-fluorescein conjugate 
Cholesterol-fluorescein conjugate was synthesized by reacting NHS-Fluorescein 
with Cholesterol-ethylene diamine in 1:1 molar ratio for 24 hr at room temperature in 
dichloromethane (1 ml) and pyridine (0.2 ml). The product was purified by column 
chromatography. 
3.1.3 Preparation of fluorescent nanoliposomes 
1- Organic solvent evaporation and lipid film formation 
Initial trials started with PC, cholesterol and DSPE-PEG (amino or carboxy or 
methoxy) with different ratios in order to reach the best preparation in terms of stability, 
loading efficiency, size homogeneity and surface charge. The final optimized formulas 
were prepared as follows, in a round bottom flask,  3 different formulations have been 
prepared and dissolved in 3 ml anhydrous DCM; A) DOTAP:DPPC: Cholesterol-
fluorescein: Cholesterol( for DOTAP liposomes ), B) DOPG:DPPC: Cholesterol-
fluorescein: Cholesterol ( for DOPG liposomes) with mol % (20:60:5:15) respectively 
for both and C)  DOPC:DPPC: Cholesterol-fluorescein: Cholesterol ( for DOPC 
liposomes ) with mol % ( 70:10:5:15) respectively. After that, the flask was mounted on 
the rotavap at slow speed under vacuum at room temperature for about an hour. 
2- Lipid film hydration 
At this step vacuum is completely released and 3 ml of double distilled H2O were 
added to the flask. After that, the temperature of the water bath was kept from 50 oC to 
60 oC. Rotation was maintained for another hour allowing the hydration of the lipid film 
layer. 
3- Extrusion 
For obtaining liposomes at size ranges between 150 to 200 nm, the whole 
suspension was forced through the polycarbonate Whatman membrane ( 0.2 or 0.4 µm) 
for about 25 times. Extrusion was done here at 60 oC Figure 3.1-1. 
 
 
 
 
 
 
 
                Figure 3.1-1 Conventional liposome preparation method (lipid film hydration) 
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3.1.4 Characterization and stability of the prepared nanoliposomes  
 
The mean particle sizes of the 3 sets of nanoparticles were measured by Dynamic 
Light Scattering method using Zetasizer Nano ZS90, Malvern (Worcestershire, UK). 
10μL of nanoparticles solution was diluted to 1ml using DI water and 3 sets of 10 
measurements each were performed at 90 degree scattering angle to get the average 
particle size. The zeta potential was measured and the nanoparticles were diluted in 
water. The physical stability of the nanoparticles was evaluated by measuring changes 
in mean particle size and zeta potential during storage condition at 4ºC.  
 
3.1.5 Ex-vivo studies on B16/F10 melanoma model: 
 
B16/F10 cells (ATCC) were cultured in DMEM, life technologies (CA, USA) and 
suspended at 2 x106 cells per 0.5 ml in PBS (kept on ice) directly before injection. The 
right hind flanks of 20 C57BL/6 black mice (10 weeks age) were shaved before the 
subcutaneous injection of 100 µl of the cellular suspension. Mice were euthanized with 
carbon dioxide when any one tumor dimension was ∼100 mm3, when exhibiting any 
sign of sickness, or at 10 days post-treatment for FACS analyses studies. The mice were 
divided into 4 groups, each 5 mice were assigned to certain immune cell line Figure 
3.1-2. 
 
 
3.1.5.1 Isolation of tumor infiltrating immune cells 
 
CD11c DCs, CD11b macrophages, CD90.2 T cells and CD49b NK cells were 
isolated from B16 melanomas according to Stem Cell Technologies. Subcutaneous 
tumors were removed  from all mice, minced into tiny sections of approximately 3-4 
mm then placed in 10 mL of serum free RPMI media, life technologies (CA, USA) 
containing 175 U/mL of Collagenase IA, Sigma ( MA, USA). The tissue was manually 
homogenized for several times and the tissue suspension was kept for 1 hr at 37ºC, 
passed through a 70-μm tissue filter and  cells were washed twice in serum free RPMI 
media and twice with PBS. The pellet was re-suspended in the recommended media 
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(PBS + 2% FBS with 1 mM EDTA) according to StemCell Technologies positive 
selection kit protocol for each cell line. The purity was assessed by FACS and reached 
to 85- 95% purity Figure 3.1-3. 
 
Concept behind labelling of mouse cells: Initially cells of interest are labelled 
with PE-labeling agent. Followed by labeling with dextran-coated magnetic 
nanoparticles via Tetrameric Antibody Complexes. Magnetically labeled cells are then 
separated from unlabeled cells using the EasySep magnet Figure 3.1-4.  
 
Figure 3.1-2 Ex-vivo studies on B16/F10 melanoma model. a) Shaving of the right hind flank. 
b) Subcutaneous injection of B16/F10 melanoma cells. c) Monitoring the tumor growth on 
daily basis. d-e) Resection of the subcutaneous tumor. f)Dissection of spleen. 
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   Figure 3.1-3 Steps for positive selection of labeled cells with EasySep® Mouse PE-labeling 
reagent. Same procedure for CD11c, CD11b, CD90.2 and CD49 cells, the only variable is the 
incubation times78 
 
 
 
 
-  
 
 
 
 
 
 
 
            
                     Figure 3.1-4 Scheme for magnetic labeling of cells via EasySep technique79 
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3.1.5.2 Isolation of spleen infiltrating immune cells 
 
Spleens were dissected from the same 20 C57BL/6 black mice at the same setting 
of tumor resection. For preparation of single cell suspension of CD11c DCs according 
to Stem Cell Technologies protocol, spleen dissociation media (SDM) was used to get 
the optimum recovery of DCs from mouse spleen. The media contained DNase, 
Collagenase IV and Fetal bovine serum (FBS). Procedure as follows: In a 60 mm 
Treated Tissue Culture Dish, the freshly isolated spleens are minced using dissection 
scissors and forceps into a homogeneous paste. Contents of the SDM were poured into 
the dish and mixed using pipette. All spleen fragments were returned back to the original 
SDM tube, Incubated horizontally on rocking platform for 30 minutes at room 
temperature. Spleen fragments were dissociated by gentle passing through 16 gauge 
needle. The entire suspension then was poured through 70 μM mesh filter into a 50 mL 
conical tube. The empty SDM tube and mesh filter were rinsed with an additional 
recommended medium and added to 50 mL conical tube, centrifuged at 1000 rpm for 
10 minutes. Supernatant was discarded and cells were resuspended in appropriate 
amount of recommended medium. Then the previous mentioned position isolation 
procedure was used.78  
 
 
For preparation of single cell suspension of CD11b macrophages, CD90.2 T-
cell and NK cells: Spleen was dissociated in the recommended medium. Remaining 
debris was removed by passing cell suspension through 70 μm strainer into a 50 mL 
tube, centrifuged and supernatant was discarded then pellet was re-suspended in the 
recommended media. After that, CD11b macrophages and CD90.2 T-cells were isolated 
by the previous mentioned positive isolation procedure, while NK cells were isolated by 
negative selection technique according to Stem Cell Technologies Figure 3.1-5. The 
unwanted cells this time were specifically labeled with dextran-coated magnetic 
particles.  
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                            Figure 3.1-5  Negative Selection procedure for Mouse NK Cell80 
   
After isolation of the target cells from the melanoma tumor and spleen, absolute 
cell numbers were assessed by direct counting on a Coulter cell counter then 10^5 cells 
were cultured in 24-well plates in a complete RPMI media (RPMI 1640, 10% FBS, 1mM 
sodium pyruvate, 0.05mM 2-mercaptoethanol, 100 µg/ml streptomycin and 100 µg/ml 
penicillin) at 37ºC in a 5% CO2 humidified atmosphere for 24 hours.  
 
3.1.6 Cellular uptake of nanoparticles by spectroflourometer and flow cytometry 
 
The three types of nanoparticles ( DOTAP, DOPG and DOPC ) were added at equal 
concentrations 158µg/ml to the four immune cell lines in the 24-well plates and kept at 
37ºC in a 5% CO2 humidified atmosphere for 4 and 18 hrs. The treatment media were 
discarded, and the cells were then gently washed with PBS twice to remove unbound 
nanoparticles. A standard curve of Cholesterol-fluorescein was generated by measuring 
the fluorescence at 520 nm using spectroflourometer. A known concentration of 
nanoparticle was dissolved in DMF and the absorbance value at 520 nm was used to 
calculate the loading from standard curve. Loading efficiency was calculated as 
incorporated dye concentration / initial dye concentration x 100 and then normalized 
with amount of protein per cells measured by BCA assay. The uptake was expressed as 
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the fluorescence associated with the cells (concentration of Cholesterol-fluorescein in 
µg) measured by spectrofluorometer (RF-5301PC, SHIMADZU) versus the protein 
concentration of these cells (concentration of protein in µg).  Cells were then acquired 
to flow cytometry (accuri C6), gating was done based on CD11c-PE, CD11b-PE, NK-
PE and CD90.2-PE expressions then florescence intensity was measured based on this 
gate. Mean fluorescence intensity was measured as well.  
 
 
3.1.7 Statistical analysis  
 
Statistical analysis was performed using one way and two way ANOVA.  
Differences were judged to be significant at p < 0.05. 
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3.2 Second part: Synthesis of pegylated LLL12 liposomes and testing 
against dendritic cells 
 
3.2.1 Materials 
 
 All reactions were done under inert procedures. Dichloromethane (DCM), 
anhydrous DCM, Methanol, Cholesterol, Dimethylamino Pyridine (DMAP), Succinic 
Anhydride, Sodium Sulfate, Pyridine, 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC), L-α-phosphatidylcholine. LLL12 was purchased from Calbiochem. 1,2-
Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Amino(Polythylene Glycol)2000], 
PC and the Extruder kit were bought from Avanti Polar Lipids. Thin layer 
chromatography was performed using silica gel (Fluka Analytical). Spots on the TLC 
plates were visualized under UV light, and/or by treatment with alkaline permanganate 
solution followed by heating. MTS reagent was supplied by Promega. Column 
chromatography was conducted using silica gel (230-400 mesh) Qualigens. 
 
3.2.2 Coupling of succinic anhydride to Cholesterol 
 
200 mg cholesterol, 155 mg Succinic anhydride and 50 mg DMAP were dissolved 
in 1 ml anhydrous pyridine, 1 ml DCM and 1 ml methanol. The reaction was flushed 
with argon and allowed to stir under argon atmosphere for 24hr. Then pyridine was 
removed under vacuum. Completion of the reaction was confirmed by performing a 
TLC in 1% Methanol in DCM solvent mixture.  
 
3.2.3 Synthesis of LLL12-Cholesterol conjugate 
 
LLL12 (10 mg, 0.0330 mmol) was dissolved in 2 ml anhydrous DCM followed by 
addition of cholesterol-succinic acid (16 mg, 0.0330 mmol), EDC (12.65 mg. 0.0660 
mmol) and DMAP (8 mg, 0.0660 mmol). The reaction mixture was flushed with argon 
and kept under argon atmosphere at room temperature for 48hr. Completion of the 
reaction was confirmed by performing a TLC in 1% Methanol in DCM solvent mixture, 
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then the solvent was evaporated under vacuum and the crude product was obtained, 
yellow solid LLL12-cholesterol conjugate ( 10 mg ). 
 
      
 
3.2.4 Preparation of LLL12-Cholesterol nanoparticle 
 
3 mg (60 mol %) of L-α-phosphatidylcholine, 0.5 mg (10 mol %) LLL12-
cholesterol conjugate and 5.4 mg (30 mol %) of 1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-[Amino (Polythylene Glycol) 2000] (DSPE-PEG) were 
dissolved in 1.0 mL anhydrous DCM. Solvent was evaporated into a thin and uniform 
lipid-drug film using a rotary evaporator. The lipid-drug film was then hydrated with 
1.0 mL H2O for 1 h at 55°C. The hydrated nanoparticles were yellow in color. Extrusion 
was done at 55°C to obtain sub 200 nm particles Figure 3.2-1. A standard curve of 
LLL12-Choletserol conjugate in DMF was generated by measuring absorbance at 389 
nm using UV-Vis spectrophotometry (Shimadzu 2450). A known concentration of 
nanoparticle was dissolved in DMF and the absorbance value at 389 nm was used to 
calculate the loading from standard curve. 
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3.2.5 Nanoparticle characterization and stability studies 
 
The mean particle size of the nanoparticles was measured by Dynamic Light 
Scattering method using Zetasizer Nano ZS90 (Malvern). 10μL of nanoparticles 
solution was diluted to 1ml using DI water and 3 sets of 10 measurements each were 
performed at 90 degree scattering angle to get the average particle size. The zeta 
potential was measured and the nanoparticles were diluted in water. The physical 
stability of nanoparticles was evaluated by measuring changes in mean particle size and 
zeta potential during storage condition at 4ºC.  
 
3.2.6 Cryo-Transmission Electron Microscopy for LLL12 nanoparticle 
 
The sample was prepared by applying 3μL of sample suspension to a cleaned grid. 
Grids were stored in liquid nitrogen until transferred to the electron microscope for 
imaging. 
 
 
 
 
Figure 3.2-1 Steps of LLL12 nanoparticle synthesis 
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3.2.7 Differentiation of DCs from bone marrow leukocytes  
 
3.2.7.1 Bone marrow isolation 
 
C57BL/6 mouse (4-10 weeks) was sacrificed by cervical dislocation, abdominal 
area was wiped with 70% ethanol. Small incision was made into the skin to expose the 
hind limbs. Tibia and femur were removed placed in HBSS (Hank’s balanced salt 
solution) with 15% penicillin/streptomycin. Bones were washed six times in the same 
solution with strong shaking. Epiphyses of tibia and femur were cut off. 10 ml syringe 
was filled with HBSS plus (with 1 ml HEPES and 2ml FBS) and attached to 23G needle. 
Bone marrow (B.M) was flushed by inserting the needle in the core of the bone to an 
empty falcon tube, the red bone marrow at the core should come out, after emptying the 
whole marrow the bone turned into white transparent color. Bone marrow clumps were 
dissociated with 18G needle by drawing the solution from the falcon tube and forcefully 
shooting it back until no clumps were visible. Collected bone marrow solution was 
filtered through 70 µm cell strainer. 50 µL of the cell suspension was mixed with 50 µL 
RBC lysis buffer (1:1) and then counted using cellometer. The suspension was 
centrifuged at 1000 rpm for 10 minutes at 4°C and resuspended in the R10 media (RPMI 
supplemented with 5.5 mL P/S (100 U/ml Pencillin, 100 µg/ml streptomycin) 50 mL 
FBS (10%), 0.05 mM- 1.9 µL β-mercaptoethanol). 
 
3.2.7.2 DCs differentiation  
 
On day zero, bone marrow leukocytes were seeded at 2 million cells per 100 mm 
bacteriological petri dish in 10 ml R10 media containing 20ng/ml GM-CSF. On day 
three, another 10 ml R10 media with GM-CSF were added. On day six, half of the 
culture supernatant was collected, centrifuged and re-suspended in 10 mL fresh R10 
media containing GM-CSF and added back into the original culture plate. By day seven, 
cells were ready for use and the purity of CD11c DC population was confirmed by flow 
cytometric analysis and was found to be between 70 and 80% for the non-adherent and 
semi-adherent cell population. Also, this CD11c population was compared with 
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immature DC cell line (JAWSII – ATCC) in the sense of CD11c surface expression 
using flow cytometer also. 
 
3.2.8 Analysis of CD11c DC purity by flow cytometry 
 
Surface staining was done according to eBioscience surface staining protocols. 1 x 
105 of DCs were washed with PBS and re-suspended in flow cytometry staining buffer. 
Then, cells were incubated with APC labelled anti-CD11c antibody or the corresponding 
isotype controls at  2µL / million cells for 1 hr. on ice and protected from light, followed 
by double wash with flow cytometry staining buffer then acquired to flow cytometry.  
 
3.2.9 Generation of immunosuppressed high pSTAT3 DCs: Screening best 
condition media that can induce the highest pSTAT3 
 
Conditioned basal media from 4T1, LLC and B16 were added to the culture of DCs 
on day 7 for 24hrs, stimulated with LPS (2µg/ml) for 15 hrs. The pSTAT3 levels were 
assessed by western blot, FACS and level of cytokines were determined by Luminex 
cytokine assay. In order to make 4T1, LLC and B16 condition media, cells were 
propagated in DMEM complete till they become confluent, then incubated in a serum 
free media ( basal media ) for 48hrs in 5% CO2 atmosphere at 37°C, then added to DC 
culture reaching final concentration of 50%. 
 
3.2.10 Analysis of pSTAT3 level by flow cytometry 
 
Intracellular staining of pSTAT3 was done according to eBioscence two-step 
protocol. Cells were fixed with fixation buffer after intended time of incubation, kept in 
dark at room temperature for 60 min. After that, cells were centrifuged at 1000 rpm for 
10 minutes at room temperature, supernatant was discarded and cell pellet was re-
suspended in 1ml ice cold methanol and incubated for one 10 min. on ice. Cells were 
washed with flow cytometry staining buffer, centrifuged for 10 min at 1000 rpm, 
supernatant was discarded and pellet was re-suspended in flow cytometry staining 
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buffer. PE labeled anti-pSTAT3 antibody or isotype control was added at 2µg / million 
cells and incubated in dark at room temperature for 60 min, then washed twice with flow 
cytometry staining buffer and acquired on a flow cytometer. 
 
3.2.11 Western blot 
 
 After needed incubation period, cells were washed twice with ice cold PBS and 
protein was collected by scraping using RIPA buffer supplemented with protease and 
phosphatase inhibitor mini tablets (Thermo scientific). Amount of protein was measured 
by BCA assay and equal amount of protein lysates were electrophoresed on a 4-20% 
polyacrylamide gel, transferred to polyvinylidene membrane, and blocked in TBST in 
5% BSA. Then membranes were incubated in TBST with Phospho-STAT3 (Tyr705) 
(1:500 dilution) and actin (1:2000 dilution) antibodies (all antibodies from Cell 
Signaling Technology) overnight at 4°C. After washing with TBST, membranes were 
incubated with horseradish peroxidase–conjugated secondary antibody for 1 hour then 
washed again with TBST. Detection was done using G-box from Syngene. 
 
3.2.12 Measurement of Cytokines 
 
 IL-2, IL-6, IL-10, IL-12, IFN-gamma and TGF-beta were measured in cell lysate 
using microbeads based assays in Dr. Joseph Bonventre’s laboratory at Brigham & 
Women’s Hospital. Briefly, cell lysate samples were incubated with microbeads coupled 
with different cytokine capture antibodies (R&D systems) and recombinant proteins for 
one hour, washed three times with PBST, and incubated with different cytokine 
detection antibodies (R&D systems) for 45 min on an orbital shaker at 300 rpm. After 
the incubation, beads were washed with PBST (3X) and incubated with streptavidin-PE 
(Invitrogen) for 15 min.  Beads were washed and re-suspended in sample dilution buffer 
and analyzed using Bio-Plex 200 systems (Bio Rad). The signal from the flurochrome, 
which reflects the amount of antigen bound to the microbeads, was measured using Bio-
Plex 200 systems. Standard curve was generated using five parametric logistic analysis 
and unknown values were interpolated. 
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3.2.13 Cell viability assay 
 
Cancer cells like 4T1, B16F10 and MDA_MB_ 231 were cultured in DMEM, 
supplemented with 10% FBS and 1% of Antibiotic-Antimycotic 100x solution. For DC 
cell line, cells were cultured in  Alpha minimum essential medium with ribonucleosides, 
deoxyribonucleosides, 4 mM L-glutamine, 1 mM sodium pyruvate and 5 ng/ml GM-
CSF, 15% fetal bovine serum. For DCs derived from B.M, cells were cultured in RPMI 
supplemented with 5.5 mL P/S (100 U/ml Pencillin, 100 µg/ml streptomycin) 50 mL 
FBS (10%), 0.05 mM- 1.9 µL β-mercaptoethanol. 4T1, B16 F10 and MDA_MB_231 
were seeded at 10,000 Cells into the 96-well flat-bottomed plates, while DC cell line 
and DCs derived from B.M seeded at 100,000 cell / well. Free drug and/or drug loaded 
nanoparticles (normalized to equivalent amounts of free drug) was added in triplicates 
in 96-well plate at appropriate concentrations (1, 10, 100 nM, 1, 10, 100 μM) and then 
plates were incubated in 5% CO2 atmosphere at 37ºC. After desired period of incubation, 
cells were washed and incubated with 200 μl phenol-red free medium containing 25 μl 
of Promega aqueous solution. After the required time of incubation for optimum color 
change in a 5% CO2 atmosphere at 37ºC, the absorbance in each well was recorded at 
490 nm using plate reader. The absorbance reflects the number of surviving cells. Blanks 
were subtracted from all data and results analyzed using GraphPad Prism software. Data 
shown is mean ± SE of n=3. 
 
3.2.14 Analysis of maturation status of immunosuppressed DCs before and after 
treatments addition using flow cytometry 
 
DCs on their day 7 were incubated with B16 condition media for 16 hr at 50% final 
concentration followed by addition of IL-6 at 5µg/mL for 3 hr. then treatments were 
added (LLL12-np and LLL12-free) at 5µmole for 24 hr. in a fresh free serum condition 
media. After intended incubation period, cells were harvested, washed with PBS and 
acquired to FACS analysis for studying expression of CD11c, MHCII, CD80, CD86 ( 
surface staining ) and pSTAT3 ( intracellular staining ) according to eBioscence 
protocols. Consequently, cells were labelled with FITC conjugated anti-CD86, anti-
CD80 antibodies and anti-I-A/I-E antibodies, APC conjugated anti-CD11c and PE 
labeled anti-pSTAT3 antibody and their corresponding isotype controls. 
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Chapter four 
4. Towards understanding the preferential internalization of 
nano-liposomes with different surface charges in DCs, 
macrophages T-cells and NKs  
 
4.1 Results and discussion 
 
Immunomanipulation using material-based approaches lies under the field of 
immunobioengineering, where nanomaterials are designed as delivery vehicles to target 
and understand the immune system.81  
Manipulation of the immune response by therapeutic intervention is becoming of  
great interest owing to the significant role of immunity in the general health and disease 
control.3 APCs like Dendritic cells and macrophages are important targets for the 
particulate delivery system due to their ability to trigger cascade of events on both levels 
cellular and humoral immune response specially DCs. Successful targeting of  DCs  and 
macrophages will have a great impact on T-cell activation and priming.37,82 
Targeting APCs in general can be achieved via surface functionalization of 
nanoparticles with antibodies against specific APC surface receptor. In DCs, there are 
several receptors that are considered possible targets such as CD205, CD206 (mannose 
receptor) and CD209 (DC- S1GN). However, there is no single receptor that is uniquely 
expressed on DCs in the tumor microenvironment.83 The hypothesis here is whether we 
can target immune cells in the tumor microenvironment without the need of surface 
functionalization. 
In the context of modifying the immune reactions in the tumor microenvironment, 
we know that the immune cells, have beneficial and deleterious influence on tumor 
growth. In-vivo studies revealed that animal models showed NK-cells and T-cells been 
involved in stress and damage removal that might turn into cancer. The design of cancer 
immunotherapy aims at directing the immune system against the tumor, and this is of  a 
great interest since the success of the first cancer vaccine.84 An essential need today for 
the design of successful particulate system that can elicit preferential targeting towards 
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specific immune cell in the tumor microenvironment. This might represent a novel 
avenue for enhancing the antitumor immunity.  
In most cases immune cells are infiltrating the progressing tumors. These immune 
cells comprise DCs, and tumor associated macrophages, Tregs and NKs. The TDFs act 
as a fuel for tumor growth rendering these tumor infiltrating cells malfunctioned.85 A 
major hurdle facing cancer immunotherapy today is the high nonspecific systemic 
toxicity that is elicited by antibodies or stimulatory cytokines. Local immuno-targetting 
within the tumor microenvironment might provide efficient strategy that can avoid 
systemic toxicity. Providing passive targeting ability to the particulate system like 
surface charge might offer a platform for preferential targeting for critical immune cells 
residing in spleen and tumor. Moreover, test whether there will be differences in uptake 
according to certain preference towards certain surface charge in specific time frame. 
Liposomes are made of phospholipid bilayer with a composite nature. Their 
properties are highly linked to their physicochemical characteristics such as size, surface 
charge and composition. These physicochemical properties can trigger certain immune 
response. Liposomal preparations are known with their improved stability either in-vitro 
or in-vivo.86 Cationic liposomes like DOTAP and DOTMA are lipid vesicles with 
positive surface charge that have been extensively studied as successful delivery 
vehicles for nucleotides such as DNA, siRNAs, and others. They showed superior 
adjuvant effects in comparison to anionic and neutral charged liposomes.87,88 
Many approaches have utilized different ways of actively targeting cancer cells 
using functionalized nanoparticles with antibodies or pH sensitive linkers, heat sensitive 
polymers, etc. The major hurdle in the nano-immunology field is to target immune cells 
within the tumor microenvironment,  because most of the immune cells do not express 
unique surface marker that can be directly targeted in the tumor environment and ignore 
the other healthy populations in the rest of the human body. In addition, the ratio of 
cancer cells to immune cells in any tumor is very high which hinder reaching the 
immune cells. Today, there is crucial need to define a strategy to reprogram those 
immune cells to be able to reverse their downregulated status and render them 
immunoresponsive instead of immunosuppressive.  
In the current study, we report rational design for fluorescent labelled nano-
liposomes that are considered as a model for different surface charges. These liposomes 
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were meant to have different surface charges according to the molar % of the lipid of 
interest. Incorporation of fluorescein as a stable fluorescent dye within the liposomal 
preparation that can be tracked in-vitro and in the future in-vivo studies requires rational 
design. Based on previous studies, the high stability of the incorporated moiety within 
liposome was observed when being conjugated to cholesterol. Cholesterol helps better 
physical attachment to the rest of the lipid structure89. Here, we conjugated Fluorescein-
NHS to cholesterol via stable ethylene-diamine amide bond. The reaction was 
characterized by 1H NMR spectroscopy as shown in the figure below. The 1H-NMR 
spectra for cholesterol shows signals attributable to protons of methane, methylene and 
methyl groups ranges from δ 0.6 to δ 2.3. Ethylene diamine shows signals attributable 
to protons of amine groups at δ 4.5, δ 5.5 and to protons of methylene at δ 3.4, δ 3.5. 
Fluorescein shows signals attributable to protons of hydroxyl group at δ 7.9, carboxylic 
group at δ 8.1 and protons of aromatic rings at δ 6.5, δ 6.8, δ 7.2 and δ 7.4. 
 
        Figure 4.1-1 1H NMR spectra of cholesterol-ethylenediamine Fluorescein-NHS conjugate 
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4.2 Nanoparticles optimization 
 
The main goal was to engineer three different nanoparticles via lipid film hydration 
method with nearly same size but different only in surface charge. Through utilizing 
three different surface charged liposomes, we will be able to establish a hit comparison 
between the internalization of specific charge among different immune cell lines in two 
different contexts, tumor microenvironment and lymphoid organ like spleen in two time 
frames 4 and 18 hrs. 
Initial trials started with PC, cholesterol and DSPE-PEG (amino or carboxy or 
methoxy). Different ratios of each component have been tested in order to reach the best 
preparation in terms of stability, loading efficiency, size homogeneity and surface 
charge. Different PEG moieties have been used in order to establish different surface 
charges using PEG amino, carboxy or methoxy. PEG itself is a bulky group that has its 
own hydrophilic nature and stealth effect and also plays a major role in elongation of 
the circulation half-lives upon in-vivo studies. It was noticed throughout the 
optimization trials that PEG plays a role in hindering the charge of the linear chain 
moiety (amino, carboxy or methoxy) in a non-proportional manner. For example, it was 
expected that by decreasing the percentage of DSPE-PEG-methoxy from 10 to 1%, the 
overall surface charge will decrease in a proportional manner, but surprisingly the 
opposite happened. The same case happened also in case of DSPE-PEG carboxy and 
amino. Table 4.2-1 illustrates the various preparations that have been tested. This led us 
to think of different compositions of liposomes without having any kind of surface 
modification, in order to have a systematic kind of surface changes that is to an extent 
in proportional to the lipid composition changes.  
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Table 4.2-1 Optimisation trials using different charged pegylated lipids 
 
 
 
Consequently, in an attempt to achieve the previous mentioned goal, we decided to 
optimize the positive, negative and near neutral surface charges using liposomes with 
the required charge without having PEG. Meaning, in case of positive surface charge 
we used DOTAP, for the negative surface charge we used DOPG, and for the neutral 
we used DPPC, DOPC and PC. Cholesterol was meant to be added to increase the 
liposome stability. Different optimization trials have been done as shown in Table 4.2-
2 and 4.2-3 to reach a good magnitude of negative and positive surface charges and near 
neutral surface charge with near sizes. DPPC and cholesterol were coupled with the final 
optimized preparations as their presence neutralizes the charges, acts as neutral nontoxic 
co-lipid and enhances the overall stability.90 
 
 
 
 
DSPE-PEG 
(type) 
 
DSPE-PEG 
mol% 
PC  
mol% 
Cholesterol 
mol% 
   Mean particle 
diameter (nm) 
Zetapotential     
(mV) 
Amino   10% 
DSPE-PEG 
70% PC     20% 
cholesterol 
435 nm +9.3 
Methoxy 10% 
DSPE-PEG 
70% PC     20% 
cholesterol 
185 nm -21.6 
Carboxy 10% 
DSPE-PEG 
70% PC      20% 
cholesterol 
116 nm -19 
Carboxy  1%  
DSPE-PEG 
75% PC      24% 
cholesterol 
179.2 -45.2 
Methoxy  1%  
DSPE-PEG 
75% PC      24% 
cholesterol 
181 -36.1 
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Table 4.2-2 Optimization trials using DOPC, DOPG, DOTAP and DPPC lipids 
 
NP (type) Lipid 1             
mol % 
Lipid 2              
mol % 
Cholesterol 
     mol% 
Mean particle 
diameter  
(nm) 
Zeta 
potential 
(mV) 
Anionic 20%DOPG 60%DPPC       20% 
Cholesterol 
183 -33.9 
Neutral 80% DPPC       20% 
cholesterol 
315 -21.2 
Cationic        5% 
DOTAP 
75%DPPC 20%Cholesterol 177 +74.8 
Cationic     20% 
DOTAP 
60%DPPC 20%Cholesterol 210 +47.7 
Cationic 35%DOTAP 35%PC 30% cholesterol 155 +42.8 
Neutral 80%DOPC  20%Cholesterol 159 -4 
Neutral 35%DOPC 35%DPPC 30% cholesterol 143 -11 
 
Table 4.2-3 Final optimized fluorescent nano-liposomes 
      NP (type) Lipid 1             
mol % 
Lipid 2             
mol % 
Cholesterol 
         mol% 
Mean particle 
diameter (nm) 
Zeta 
potential 
(mV) 
        Cationic 20% 
DOTAP 
60%DPPC 15% 
Cholesterol, 
5%  
220 +36 
       Negative 20% DOPG 60%DPPC 15% 
Cholesterol 
190 -48 
   Near neutral 70% DOPC 10%DPPC 15% 
Cholesterol 
210            -17.4 
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4.3 Nanoparticles characterization 
 
4.3.1 Mean particle size and zeta potential for DOPG, DOTAP and DOPC  
 
The mean particle size distribution, poly dispersity index and zeta potential of the 
nanoparticles were determined by Dynamic Light Scattering method (n=10 
measurements per sample) and performed at 25oC on a DLS-system (Malvern 
NanoZetasizer). We were able to engineer three sets of fluorescently labelled nano-
liposomes as a model for different surface charges, the anionic DOPG NP, cationic 
DOTAP NP, and near neutral DOPC NP with mean diameter of 190, 220, 210 nm and 
Zeta Potential of -48, +36 and -17.4 mV respectively as shown in the figures below.  
 
 
 
 
Figure 4.3-2 The distribution of hydrodynamic diameter and zeta potential of DOTAP 
nanoparticle 
Figure 4.3-2 
Figure 4.3-1 The distribution of hydrodynamic diameter and zeta potential of DOPG 
nanoparticle 
Figure 4.3-1 
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4.3.2 Fluorescein loading efficiency (Spectrofluorimetric analysis) 
 
The amount of Cholesterol-fluorescein that was incorporated successfully in the 
nanoparticles after extrusion step was determined using spectrofluorometer. Initially a 
standard curve was established using different serial dilutions for the three preparations 
by plotting absorbance intensity on Y-axis and the corresponding concentration on X-
axis, given that the emission maximum of fluorescein is around 521 nm. Accordingly, 
the concentration of the nanoparticles was calculated from this standard curve using the 
following formula: y = 133607x + 51.822, R² = 0.985 Figure 4.3-4. The loading 
efficiency was determined as the concentration of fluorescein recovered after extrusion 
compared to the initial loading amount. It is important to mention that the 3 preparations 
were normalized to each other in terms of concentration before adding to the cells. As 
each well was loaded with exact same concentration of nanoparticles per volume and 
almost nearly same sizes, so the only variable was the surface charge.  
 
Figure 4.3-3 The distribution of hydrodynamic diameter and zeta potential of DOPC 
nanoparticle 
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                                   Figure 4.3-4 Cholesterol-fluorescein conjugate standard curve 
 
4.3.3 Physical stability of the nanoparticles 
 
The physical stability for the final optimized three types of fluorescent nano-
liposomes was then assessed by monitoring the changes in particle size and zeta 
potential during storage at 4oC, shown in Figure 4.3-5. The three preparations showed 
a stability to a great extent over a test period of 20 days. The magnitude of change either 
in the size or in the total surface charge was not that much significant. The stability data 
was collected on daily bases using DLS that was being used on triplicate basis for each 
single measurement. The most significant criteria was the absence of precipitation or 
turbidity during the test period. We can say that the three preparations are physically 
stable with minor non-significant changes which suggest a good and stable delivery 
system for future applications, given that the storage temperature is 4oC. 
 
 
 
 
Figure 4.3-5 Physical stability of DOTAP, DOPG and DOPC nanoparticles respectively 
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4.4 Uptake efficiency and flow cytometric analysis  
 
In agreement with previous studies that showed different uptake patterns of 
positive, negative and neutral surface charged liposomes with different cancer cell 
lines91, results here reveal differences in the preferential uptake and internalization of 
different surface charged fluorescent labelled liposomes between different immune cell 
lines; macrophages, DCs, NKs and T-cells which were isolated from the tumor and from 
the spleen.  
In case of DCs, two-way ANOVA analysis revealed that in spleen DCs, number of 
incubation hours was not significant ( p > 0.05 ) , however type of NP was significant   
( p < 0.001) and the interaction between both number of incubation hours and type of 
NPs was significant as well ( p < 0.001 ). In case of tumor DCs, number of incubation 
hours was significant by itself (p < 0.01), type of NPs alone or when combined with the 
effect of incubation hours were barely significant (p < 0.05). The previous results reflect 
how type of NPs and hence their surface charge showed significant effect in the uptake 
and hence the internalization pattern in both microenvironments (spleen or tumor). Also, 
number of incubation hours was not significant in case of spleen DCs in contrast to 
tumor DCs, which proves the sensitivity of tumor DCs to the incubation times. In order 
to reach more conclusive results and get detailed analysis for each NP, one-way 
ANOVA was used based on the previous preliminary statistics. In this test we analyzed 
the effect of NP type on combined conditions, type of cells and incubation hours. It has 
been revealed in case of spleen DCs of 4 hours incubation, DOTAP NP showed 
significant internalization (p < 0.001). In case of tumor DCs of 4 hours incubation, 
DOPC NP showed significant internalization (p < 0.05). DOPG NP did not show any 
significant pattern either in spleen or tumor DCs (p > 0.05).  It is important to mention 
that 18 hours incubation in either tumor or spleen did not show any significant 
preferential internalization of a particular NP over another Figure 4.4-1. 
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Figure 4.4-1 Uptake efficiency of DOTAP, DOPC, and DOPG NPs by DCS from spleen and tumor 
after 4 and 18 hours. The uptake was expressed as the fluorescence associated with the cells 
(concentration of fluorescein in µg measured by spectrofluorometer) versus the protein 
concentration of these cells (concentration of protein in µg measured by BCA assay).   
A possible postulate is the variation of receptors distribution in DCs between tumor 
and spleen, i.e. the surface heparane sulfate proteoglycan which is negatively charged 
receptor might be expressed with higher levels in case of spleen DCs than tumor DCs 
that leads to a higher uptake of positively charged DOTAP NP in spleen than tumor. 
Although DOTAP has been mentioned extensively in the literature for being efficiently 
internalized within most of the cells owing to its cationic nature, DOPC which is neutral 
charge phospholipid was also used to deliver nucleotide cargos in tumor cells at 10 to 
30 folds higher than cationic liposomes like DOTAP.92 This can explain the preferential 
DOPC uptake in 4hr incubation time in case of tumor DC. One advantage of DOPC over 
DOTAP is the much less stress and toxic effects that could be elicited from the presence 
of cationic group.93 The idea of having neutral liposomes as a delivery targeting carrier 
is of a great interest as their neutral nature limits the interaction with the DNA.90 The 
mentioned results are particularly interesting because this could open a new avenue for 
developing therapeutic platform with a neutral charge that can efficiently targets DCs in 
tumor microenvironment. These results were confirmed by FACS analysis and mean 
fluorescence intensity as shown in Figure 4.4-2, where shifts in fluorescence NPs on x-
axis ( red histograms ) are represented  in comparison with untreated cells ( black 
histograms ). Higher shifts were observed in DOPC NP in tumor DCs and DOTAP NP 
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in spleen DCs. The difference between uptake pattern in DCs in tumor and spleen is due 
to the difference in the microenvironment context. 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
4.4-2 Representative FACS data of CD11c DCs isolated from tumor model and spleen treated with 
DOTAP, DOPG and DOPC nanoparticle. cells were incubated with the nanoparticles for 4hr (top) and 
18 hr (bottom)  kept at 37ºC in a 5% CO2 humidified atmosphere followed by washing with PBS to 
remove excess unbound nanoparticles. The mean fluorescence intensity of cells was measured by flow 
cytometry.  Data shown are mean ± SD from n=3. Gating was done based on CD11c-PE expressions 
then fluorescein intensity was measured based on this gate.  Shifts in fluorescence histograms on X-
axis are shown in this figure. Mean fluorescence intensity was measured as well. 
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In macrophages Figure 4.4-3, two-way ANOVA analysis revealed that in spleen 
macrophages number of incubation hours and type of NP were significant (p < 0.001) 
however, interaction between these two parameters was not significant (p > 0.05). On 
the other hand, tumor macrophages showed the same pattern, except that number of 
incubation hours (p < 0.001) was much more significant than type of NP (p < 0.01) and 
this is in agreement with tumor DCs that showed high sensitivity to the effect of time. 
There was some interaction between incubation hours and type of NP in tumor 
macrophages that was barely significant (p <0.05). In the one-way ANOVA, DOTAP 
NP showed significant uptake pattern over other NPs in 4 and 18hr spleen macrophages 
and 18 hour tumor macrophages (p < 0.01, 0.05 and 0.05 ) respectively. The 4 hour 
tumor macrophages was not significant (p > 0.05). DOPC NP and DOPG NP did not 
show significant pattern (p > 0.05). These results were confirmed by FACS analysis and 
mean fluorescence intensity as shown in Figure 4.4-4. In which, DOTAP NP showed 
higher histogram shifts in spleen and tumor macrophages in comparison to DOPG and 
DOPC NP in 4 and 18 hr incubation time. 
 
  
Figure 4.4-3 Uptake efficiency of DOPC, DOTAP and DOPG NPs by Macrophage from spleen and 
tumor after 4 and 18 hours. The uptake was expressed as the fluorescence associated with the cells 
(concentration of fluorescein in µg measured by spectrofluorometer) versus the protein 
concentration of these cells (concentration of protein in µg measured by BCA assay).   
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4.4-4 Representative FACS data of CD11b macrophages isolated from tumor model and spleen 
treated with DOTAP, DOPG and DOPC nanoparticle for 4 and 18hrs. Cells were incubated with 
the nanoparticles for 4hr (top) and 18 hr (bottom)  kept at 37ºC in a 5% CO2 humidified 
atmosphere followed by washing with PBS to remove excess unbound nanoparticles. The mean 
fluorescence intensity of cells was measured by flow cytometry.  Data shown are mean ± SD from 
n=3. Gating was done based on CD11b-PE expressions then fluorescein intensity was measured 
based on this gate.  Shifts in fluorescnece histograms on X-axis are shown in this figure. Mean 
fluorescence intensity was measured as well.  
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These results are inconsistent with previous studies that showed preferential uptake 
of anionic NPs due to the presence of scavenger receptors in macrophages that favor 
interaction with anionic groups.94 The present results might be attributed to the existence 
of TLRs (Toll like receptors) which enhance the uptake of NPs. In some cases, TLRs 
are upregulated under stress conditions95 which can explain why DOTAP NPs were 
internalized by high concentration in case of tumor and spleen macrophages. By 
comparing the behavior of macrophages versus DCs, it is observed that DCs show 
different uptake patterns between spleen and tumor microenvironments while 
macrophages showed almost the same uptake pattern in the two microenvironments. 
This is considered as a distinguished difference in particular between macrophages and 
DCs in the 4 hour time window. Selective targeting of DCs and macrophages separately 
in the tumor microenvironment i.e. DOPC NP for DCs and DOTAP NP for macrophages 
could be achieved via utilizing the release kinetics pattern of the nano-particulate 
system. 
 
In case of T-cells and NK-cells, the first observation was that there is no preferential 
uptake of certain NP over the other. T-cells did not show significant uptake of particular 
NP either in spleen or tumor T-cells, actually most of NPs were internalized Figure 4.4-
5. However, in case of NK-cells the incubation time was very significant in spleen and 
tumor NK-cells (p < 0.001). The degree of uptake of the three NPs in general was higher 
in case of 18hrs than 4hrs incubation time in both tumor and spleen Figure 4.4-7. The 
previous results were attributed to the absence of a parameter that controls the 
preferential uptake of specific charged NP. Flow cytometric analysis confirmed some 
of these observations as shown in Figure 4.4-6 and 4.4-8.  
 
In this study, we have shown that some immune cells have different uptake pattern 
of different surface charged liposomes depending on the context they are presented in, 
whether spleen or tumor microenvironment. A full clear understanding of the optimum 
liposomal preparation that can be used as a platform for a therapeutic cargo still needs 
further investigations in terms of the nature of the uptake mechanism and the endocytic 
pathways. Interaction of lipid-based nanoparticles with immune cells offers a new 
avenue to explore targeting patterns within immune system and hence develop 
successful targeted delivery to certain subsets of immune cells.  
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Figure 4.4-5 Uptake efficiency of DOTAP, DOPC, and DOPG NPs by T-cells from spleen and tumor 
after 4 and 18 hours. The uptake was expressed as the fluorescence associated with the cells 
(concentration of fluorescein in µg measured by spectrofluorometer) versus the protein 
concentration of these cells (concentration of protein in µg measured by BCA assay).   
 
 
 
 
 
 
 
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4-6 Representative FACS data of CD90.2 T-cells isolated from tumor model and spleen 
treated with DOTAP and DOPG nanoparticle for 4 and 18 hrs. Data shown are mean ± SE from 
n=3. Cells were incubated with the nanoparticles for 4hr (top) and 18 hr (bottom)  kept at 37ºC in 
a 5% CO2 humidified atmosphere followed by washing with PBS to remove excess unbound 
nanoparticles. The mean fluorescence intensity of cells was measured by flow cytometry.  Data 
shown are mean ± SD from n=3. Gating was done based on CD90.2-PE expressions then fluorescein 
intensity was measured based on this gate.  Shifts in fluorescense histograms on X-axis are shown 
in this figure. Mean fluorescence intensity was measured as well.  
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Figure 4.4-7 Uptake efficiency of DOTAP, DOPC, and DOPG NPs by NK cells from spleen and 
tumor after 4 and 18 hours. The uptake was expressed as the fluorescence associated with the cells 
(concentration of fluorescein in µg measured by spectrofluorometer) versus the protein 
concentration of these cells (concentration of protein in µg measured by BCA assay).   
 
 
 
 
 
 
 
 
 
58 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4-8 Representative FACS data of NK cells isolated from tumor model and spleen treated 
with DOPC, DOTAP and DOPG nanoparticle for4 & 18 hrs. Data shown are mean ± SE from n=3. 
Data shown are mean ± SE from n=3. Cells were incubated with the nanoparticles for 4hr (top) and 
18 hr (bottom)  kept at 37ºC in a 5% CO2 humidified atmosphere followed by washing with PBS to 
remove excess unbound nanoparticles. The mean fluorescence intensity of cells was measured by 
flow cytometry.  Data shown are mean ± SD from n=3. Gating was done based on CD90.2-PE 
expressions then fluorescein intensity was measured based on this gate.  Shifts in fluoresence 
histograms on X-axis are shown in this figure. Mean fluorescence intensity was measured as well. 
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Chapter five 
5. Towards development of novel pegylated LLL12 lipid 
nanoparticle as a STAT3 inhibitor in DCs: proof of 
concept 
 
5.1 Results and discussion 
 
A promising approach that can reverse the immunosuppressed status of DCs is 
STAT3 inhibition. In cancer, STAT3 is highly expressed in cancer cells as well as DCs. 
Despite the potent STAT3 inhibitory effects of LLL12, there are some limitations facing 
the clinical trials (in-vivo) which hinder the achievement of the high potency achieved 
on cell lines (in-vitro), e.g. poor water solubility, nonspecific side effects and lack of 
sustained release over a certain window of time. Novel applications like nano-carriers 
represent a promising approach of drug delivery systems that will enhance the efficacy 
of the therapeutic agent and help overcome the existing limitations.  
NPs loaded with small molecular inhibitor like LLL12 aim to inhibit STAT3 in a 
sustained fashion in comparison to free drug.96 Development of pegylated liposomes 
containing chemically conjugated LLL12 to cholesterol is being investigated in this 
study as a strategy for a controlled delivery of LLL12 to tumor and dendritic cells. 
Liposomes act as a biocompatible and biodegradable lipid based carrier that is approved 
by FDA.89 These lipid based nanoparticles can provide a platform for safe and sustained 
delivery to DCs, paving the way towards efficient cancer nano-immunotherapy. To our 
knowledge, this is the first time liposomes are used as a carrier for STAT3 inhibitor and 
LLL12 as well as is investigated for the first time against a new cell line like dendritic 
cells. The hydroxyl group of LLL12 was conjugated via an ester bond to cholesterol-
succinate complex. The product was characterized by mass spectrometry, shown in 
Figure 5.1-1. The parent peak at 794.37 m/z is corresponding to LLL12-Cholesterol 
conjugate. 
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                              Figure 5.1-1 Mass spectra for LLL12-Cholesterol conjugate 
In the present work, pegylated liposomes were chosen in order to achieve better in-
vivo kinetics upon animal trial. PEG chain is cross linked to DSPE to elicit a lot of useful 
properties, as it is biocompatible, soluble and exert low antigenicity with a good 
excretion profile. Polyethylene glycols increase the stability of the drug and increase the 
circulation time of the cargo leading to an increase in the half-life and a decrease in the 
rate of clearance. A possible postulate for the reason behind eliciting extended half-life 
is the reduced interaction with the surface proteins due to the exerted steric hindrance.97 
PC and cholesterol were selected in the liposomal preparation as they are natural 
components of the biological membrane.89 The engineered NP from DSPE-PEG, PC 
and LLL12-Chol at optimized molar ratios via lipid film hydration scheme is shown in 
Figure 5.1-2. The loading efficiency of LLL12-Chol was 82±4% as calculated from 
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LLL12-Chol standard curve according to the following equation: drug loading 
efficiency = loaded drug concentration /initial drug concentration x 100, shown in 
Figure 5.1-3. 
 
Figure 5.1-2 Schematic representation for the assembly of nanoparticles from phosphatidylcholine 
(PC), LLL12-cholesterol conjugate and DSPE-PEG 
                                       
Figure 5.1-3 Standard curve of LLL12-Choleterol conjugate in DMF was generated by measuring 
absorbance at 398 nm 
 
y = 4.1073x + 0.0307
R² = 0.9993
0
0.5
1
1.5
2
2.5
0 0.1 0.2 0.3 0.4 0.5 0.6
A
b
so
rb
an
ce
Conc µg/µl
62 
 
5.2 Characterization of LLL12-NP 
 
The hydrodynamic diameter of this LLL12-NP is 190 ± 5 nm as determined by 
dynamic light scattering and zeta potential of 5.2 mV. Cryo-transmission electron 
microscopy (cryo-TEM) revealed the formation of predominantly unilamellar structures 
of diameter less than 200nm, shown in the figures below. 
Figure 5.2-1 The distribution of hydrodynamic diameter (left) and zeta potential (right) for 
LLL12 NP 
                                   
Figure 5.2-2  High-resolution Cryo-TEM image of LLL12-NP at low magnification (left) and high 
magnification (right). (Scale bar left, 100 nm) 
                                     
 
 
 
63 
 
5.3 Physical stability 
 
To investigate whether the conjugation of LLL12 to cholesterol shows superior 
properties over the unconjugated form in terms of physical stability, two preparations 
were tested. One preparation was 30% DSPE-PEG, 60% PC and 10% LLL12-Chol 
(conjugated form) and the other was 30% DSPE-PEG, 60% PC and 10% LLL12 
(unconjugated). By comparison, it was revealed that after day 2 the unconjugated 
preparation rapidly experienced precipitation as shown in Figure 5.3-1 (left). This is 
consistent with the previous studies that utilized cholesterol-based derivative, 
facilitating supramolecular assembly with phosphatidylcholine and DSPE-PEG.98  
      The physical stability has been assessed by monitoring the changes in particle 
size and zeta potential during storage at 4oC, shown in Figure 5.3-1 (right). The 
preparation showed a stability to a great extent over a test period of 15 days. The 
magnitude of change either in size or in total surface charge was not significant. The 
stability data was collected on daily bases using DLS which was being used on triplicate 
basis for each single measurement. The most significant criteria was that no 
precipitation or turbidity happened during the test period, given that storage temperature 
was 4oC. We can say that the preparation is stable and extended periods could be tested 
as well.  
 
 
                 
 
 
Figure 5.3-1 ( left ) Two formulations for LLL12 NP; left after conjugating LLL12 to cholesterol, 
right without conjugating LLL12 to cholesterol. (Right) graph shows the physical stability of 
LLL12-NPs during storage condition at 4°C as measured by changes in size and Zeta potential of 
nanoparticles 
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5.4 Cell viability assay 
 
The efficacy of LLL12-NP was evaluated in-vitro using BMDC (bone marrow 
derived DCs), JAWSII (DC cell line), B16F10 (Melanoma cancer model), MDA-MB-
231 (human breast cancer model) and 4T1 (murine breast cancer), ATCC Figure 5.4-1. 
IC50 values are shown in the table below. It has been observed and in agreement with 
previous studies that the conjugated form of LLL12 showed decreased potency than the 
free drug. This indicated that LLL12-NP behaves like prodrug status that needs time to 
be released with in-vivo conditions which will help its activation to the parent molecule 
for the ultimate efficacy.98  
 
Figure 5.4-1 MTS assay showing the effect of free LLL12 or LLL12-NP at different concentrations 
on MDA-MB-231 cells at 72h and 48h; 4T1 cells at 48h; Bone marrow derived DC  at 48h; DC cell 
line at 48h and B16F10 melanoma at 72h. Graphs show the effect of treatment with free LLL12 or 
LLL12-NP on viability on different cell lines. Table 5.4-1 shows IC50 of free LLL12 and LLL12 NP 
in different cell lines at 48h and 72h. Data shown are mean ± SEM (n=3, with at least triplicates in 
each independent experiment).  
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Table 5.4-1 IC50 values [µM] 
           Cell line      IC50 values [µM]            Treatment 
MDA-MB-231, 72hrs  - 3.94 
- 5.712 
- Free 
- NP 
MDA-MB-231, 48hrs - 0.38 
- 0.721 
- Free 
- NP 
4T1, 48hrs - 0.443 
- 2.954 
- Free 
- NP 
Bone marrow derived 
DC, 48hrs 
- 2.08 - Free 
DC cell line, 48hrs -  2.7 - Free 
B16F10, 72hrs - 1.588 
- 4.326 
- Free 
- NP 
 
5.5 CD11c DC purity by flow cytometry 
 
Assessment of the purity of CD11c lineage has been done by staining the cells on 
day 7 with APC labelled anti-CD11c antibody and the corresponding isotype control. 
The purity was found to be 70-80%. Then, these DCBM were compared to the JAWSII 
(DC cell line) that showed purity of 85%. Figure 5.5-1 shows FACS for DCBM on the 
left and DC cell line on the right. The cells were gated on CD11c APC channel.  
                        
 
 
 
 
Figure 5.5-1 CD11 DC expression was evaluated by flow cytometry on day 7 for the DCBM and 
compared this expression level to DC cell line. 
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5.6 Screening best condition media that can induce the highest pSTAT3 
 
In order to study which conditioning medium is potent to induce high levels of 
intracellular pSTAT3 and consequently mimic the immunosuppressed status of DCs 
within the tumor microenvironment, three conditioning media were tested against 
DCBM for 24hrs which are 4T1, LLC and B16 media. Cells were harvested and 
acquired for western blot, cytokine analysis and FACS. Western blot showed the highest 
intensity band of pSTAT3 in case of B16 condition medium. Cytokine analysis was 
performed to evaluate the highest IL-6 secretion which was observed also in B16, then 
final confirmation was done with FACS intracellular staining with PE labeled anti-p-
STAT3 antibody, the result was in agreement with western blot and cytokine analysis, 
showing that B16 expressed pSTAT3 by 4.9% while 4T1 was 0.7% and LLC was 3.6% 
pSTAT3, Figure 5.6-1. In conclusion, B16 condition media is the best model that can 
be used to condition DCs and simulate a tumor microenvironment around them.  
 
 
   
 
 
 
  
  
 
Figure 5.6-1 (top left) Western blot analysis showing expression of pSTAT3 in DCBM after 
conditioning in different tumor basal media and actin control. pSTAT3 optical density bands were 
normalized to actin bands using ImageJ software. (Top right) Cytokine levels measured for DCBM 
after conditioning in different tumor basal media. (Bottom) Representative FACS data for pSTAT3 
expression level evaluated by flow cytometry on the different tumor basal media after 24 hrs 
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5.7 Assessment of maturation status of immunosuppressed DCs before 
and after LLL12 addition using flow cytometry 
 
FACS analysis of CD86, MHCII and CD80 expressions were performed. MHCII, CD80 
and CD86 were gated on CD11c double positive population. CD11c APC channel was on x-
axis and FITC channel on y-axis. In Figure 5.7-1 (a), normal expression of CD86, 
MHCII and CD80 were assessed in DCs in normal state on day 7. The isotype controls 
are also displayed. CD11c-CD86 showed 1.9% expression, CD11c-MHCII showed 
22.8% expression and CD11c-CD80 showed 0.6% expression.  
In Figure 5.7-1 (b) after conditioning BMDC with B16 basal media, down 
regulation occurred to the DC surface receptors and immunosuppressive state started to 
reveal. CD11c-CD86 showed 1.3% expression, CD11c-MHCII showed 5.3% 
expression and CD11c-CD80 showed 0.2% expression. 
In Figure 5.7-1 (c), after addition of IL-6 in order to induce more stress on DCs and 
add fresh stimulus that can activate the JAK-STAT pathway once again. CD11c-CD86 
showed 0.3% expression, CD11c-MHCII showed 3.4% expression and CD11c-CD80 
showed 0.1% expression.       
Figure 5.7-2 (a), represents the pSTAT3 level in normal DCs after addition of B16 
condition media and after addition of IL-6. The pSTAT3 level in normal DCs is 29.7%, 
in conditioned DCs is 77.8% and after IL-6 is 67.7%. These results are consistent and 
in agreement and with the previous results, where DCs upon conditioning, experience 
activation of JAK-STAT pathway that elicits high levels of pSTAT3 that cause the 
downregulation and immunosuppression of DC surface receptors. 
Figure 5.7-2 (b), represents FACS data after addition of LLL12-NP (5 µmole) for 
24hrs. pSTAT3 expression level decreased to 54.7% with slight upregulation in CD11c-
CD86 that showed 0.4% expression, in CD11c-MHCII that showed 4.3% expression, 
while in case of CD11c-CD80 nothing was observed. 
Figure 5.7-2 (c), represents FACS data addition of free LLL12 (5 µmole) for 24hrs. 
pSTAT3 level also decreased as in LLL12-NP. CD11c-CD86 showed 0.7% expression, 
CD11c-MHCII showed dramatic increase around 3 folds with 10.2% expression within 
only 24hrs and CD11c-CD80 almost showed no change. It is obvious that free drug 
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showed significant upregulation of CD11c-MHCII than LLL12-NP. The free LLL12 
results are consistent with the fact that NP is releasing the drug in a slow manner. This 
sustained behavior hinder the full potency of LLL12 in only 24hrs. Future work should 
test the LLL12 potency for 48hrs.  
Activation of STAT3 play a major role in cancer development, it does not only 
provoke JAK-STAT cycle within the tumor, but also influences the tumor infiltrating 
immune cells. A major affected cell is the dendritic cell that suffers from 
immunosuppression and elicit increased numbers of immature DCs and regulatory T-
cells.99 Therefore, inhibition of STAT3 in tumor microenvironment and 
immunosuppressed DCs is a promising approach not only from the aspect of tumor 
proliferation reduction, but also to break a continuous cycle of tumor 
immunosuppression which will consequently lead to better therapeutic outcome.  
LLL12 is a recently discovered molecular inhibitor for STAT3. It is selective for 
STAT3 inhibition with no off target properties, inhibits nuclear translocation and hence 
the DNA binding. Previous studies have used LLL12 for STAT3 inhibition in tumor 
cells, but in this study we investigate for the first time whether LLL12 will exert the 
same effect on STAT3 inhibition in DCs. In the present study, we generated 
immunosuppressed DCs that experienced high levels of induced pSTAT3 through 
exposure to melanoma cell line condition media as shown in Figure 5.7-2 (a). This 
pSTAT3 induction significantly reduced DC functional maturation as shown in Figure 
5.7-1 (b). We tested whether LLL12 (5µmole) will exert immunomodulatory effects or 
no in 24hr based on its STAT3 inhibitory action. Here, we report a chemically 
conjugated LLL12 to cholesterol through esterification reaction between hydroxyl 
group of LLL12 and carboxylic group of Cholesterol-succinate. This preliminary step 
led to increase in the loading efficiency up to 80% within the lipid NP and tuned the 
release to cover extended period, and more importantly the stability of the formulation 
dramatically increased.  In the future work, in-vivo studies will be performed as we 
predict that the potency of the LLL12-NP will get multiplied upon in-vivo trials, that is 
because prodrug will get activated when the ester bond get cleaved by the action of 
esterases, and fortunately, the acidic pH of the tumor will easily cleave the ester bond 
releasing the active LLL12. In summary, the chemical conjugation of LLL12 to 
cholesterol NP serve as an efficient drug delivery platform. The developed NP was 
found to have inhibitory effects on STAT3 in DCs, however future work will be done 
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to test extended treatment periods and proceed to the in-vivo trials. In-vitro LLL12-NP 
(5µmole) reduced the pSTAT3 levels in melanoma cancer model in 24hr and restored 
the DC surface expression of CD86 and MHCII as shown in Figure 5.7-2 (b). However, 
free LLL12 (5µmole) showed superior restoration of MHCII as shown in Figure 5.7-2 
(c) which reveals that LLL12-NP needs longer time to elicit the full LLL12 effect. 
These results demonstrate the potential of LLL12 to reverse the immunosuppressed 
status of DCs in tumor microenvironment and its immunomodulatory role. If this 
construct proven successful while in-vivo studies, it will offer a promising platform for 
novel immunotherapeutic strategy. 
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Figure 5.7- 1 Representative FACS data for the expression of MHCII, CD80 and CD86 on the 
gated CD11c double positive population. Gates were set using isotype controls. (a) Data shown for 
DCs in normal state, (b) Data shown for DCs after addition of B16 condition media (c) Data shown 
for the DCs after addition of IL-6 
a) 
b) 
c) 
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Figure 5.7-2 (a)  Representative FACS data for the pSTAT3 expression in BMDC in normal state, 
after conditioning with B16F10 basal media and after addition of IL-6, FACS data for the 
expression of MHCII, CD80, CD86 on the gated CD11c double positive population and pSTAT3. 
Gates were set using isotype controls. ( b ) Data shown for the BMDC after addition of LLL12-NP 
at 5µm for 24 hrs. in a fresh B16F10 basal media, (c) Data shown for the BMDC after addition of 
Free-LLL12 at 5µm for 24 hrs. in a fresh B16F10 basal media 
 
a) 
b) 
c) 
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Chapter six 
6. Conclusion and future prospectives 
  
Material science has shown a new avenue of contribution which is the field of 
immune-bioengineering as a therapeutic drug delivery platform. This allowed us to 
better explore the interaction between different classes of immune cells and pathogens. 
Conventionally, the immune system used to instruct and dictate the fate of the material 
based intervention, however today the advances in material science are used to instruct 
the immunobiology.81 Nanoparticle based immunotherapy is still at its infancy stage of 
development. It is crystal clear that this approach offers great potentials. Studies are still 
investigating the privilege of microparticles and nanoparticles as immunotargetting 
vehicle or immunomodulatory platform. Overall, these novel strategies showed better 
yield compared with the non-particle based conventional ones. Clinical translation of 
any of these approaches require first accurate optimization of the particulate system. So 
far and despite of the positive findings, physical and chemical properties of these 
particulate delivery systems need to be crucially defined.100  
In summary, we have described different promising strategies either to target or 
modulate immune cells. More deep investigations are still needed to reveal the 
mechanisms and pathways by which certain immune cell can sense, interact and hence 
internalize certain NP. Understanding these properties will lead to improved targeted 
delivery to different immune cells.  
Understanding the possibility of preferential uptake of certain surface charged 
liposome over another in specific cell line might serve as a guideline. This can help 
better design tailored NP for a successful targeting application. We observed a tendency 
of accumulation of DOPC NPs in tumor DCs and DOTAP NPs in spleen DCs within 4 
hr. window. This suggests that DCs in two different contexts elicit different targeting 
affinities. In contrast to macrophages that showed constant pattern of DOTAP NPs 
uptake in both tumor and spleen macrophages. In T-cells, all NPs get internalized in 
both tumor and spleen T-cells. In NK-cells, all three NPs get internalized but with higher 
uptake efficiency in 18hrs treatments than 4hrs. In the future work related to this context, 
we are planning to investigate the mechanism of internalization of NPs per each cell line 
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and find out the predominant endocytic pathway. In addition, we will study the in-vivo 
biodistribution in different organs in animal trial. 
On the other hand, STAT3 is a new player in the field of cancer therapy. It has been 
proven that STAT3 represents a vital role in cancer progression, in terms of 
proliferation, invasion, angiogenesis and most importantly immunosurveillance escape. 
According to several studies, STAT3 activation is attributed to various types of human 
cancers, in addition to the immunosuppression it elicits which is our scope here. The 
inhibition of DCs functional maturation that hinders from normal expression of its 
surface receptors is a major challenge today that renders STAT3 pathway a novel target 
for cancer immunotherapy. LLL12 is molecular STAT3 inhibitor that is used for the 
first time here in cancer immunotherapy context for targeting the most professional 
antigen presenting cells like dendritic cells. It has been revealed in the current study that 
LLL12 might serve as a new player in cancer immunotherapeutics. In either free or 
conjugated form, inhibition of pSTAT3 was observed and consequently restoration as 
well as upregulation of some surface markers.  
STAT3 inhibition approach can be extrapolated to cover multiple targets at the same 
time by designing suitable combinations with chemotherapeutics. The goal is to reach 
synergy between the two therapeutic moieties. It has been revealed that STAT3 
suppression enhance the sensitivity of the cells to chemotherapy such as cisplatin and 
taxol. That is why STAT3 today is an attractive target and therapeutic designs should 
go beyond monotherapy. Our future work will entail testing the LLL12-NP for extended 
periods 48 and 72hrs. After that, proceeding to animal trial with melanoma cancer 
model, where we will use combination therapy. We might use chimeric NP containing 
STAT3 inhibitor like LLL12 and immune check point inhibitor. Another thought is to 
combine STAT3 inhibitor with chemotherapy like cisplatin or paclitaxel.    
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